Abstract
Background
Yanghe decoction is a famous formula consisting of Rehmannia, deer horn gum, cinnamon, rue, Ephedra, ginger charcoal, and licorice. However, few studies have explored the role of the potential mechanism of Yanghe decoction in the treatment of Hashimoto's thyroiditis by metabolomics.
Methods
Nine mice were randomly divided into three groups: control group (group C), model group (group M), and drug administration group (group T), with three mice in each group. Mice in groups M and T were established as models of Hashimoto's thyroiditis, and group T was treated with Yanghe decoction. The metabolome of plasma samples from each group of mice was determined using mass spectrometry coupled with high-performance liquid and gas phases, and nuclear magnetic resonance. Based on the three assays, principal component analysis was performed on all samples, as well as orthogonal partial least squares-discriminant analysis and differential metabolite molecules for groups M and T. Subsequently, pathway enrichment analysis was performed, and the intersection was taken for the differential metabolites screened in the M and T groups. The levels of inflammatory factors IL-35 and IL-6 within the serum of each group of mice were detected.
Results
The difference analysis showed that a total of 38 differential metabolites were screened based on mass spectrometry coupled with the high-performance liquid phase, 120 differential metabolites were screened based on mass spectrometry coupled with gas phase, and a total of α-glucose and β-glucose were the differential metabolites analyzed based on NMR test results. The pathways enriched by the differential metabolites in the M and T groups were intersected, and a total of 5 common pathways were obtained (amino acid tRNA biosynthesis, D-glutamine and D-glutamate metabolism, tryptophan metabolism, nitrogen metabolism, and arginine and proline metabolism). The results also showed a significant decrease in the serum inflammatory factor IL-35 and a significant increase in IL-6 in mice from group M compared with group C, while a significant increase in the serum inflammatory factor IL-35 and a significant decrease in IL-6 in mice from group T compared with group M.
Conclusion
Our study reveals the metabolites as well as a metabolic network that can be altered by Yanghe decoction treatment of Hashimoto's thyroiditis and shows that Yanghe decoction can effectively reduce the level of inflammatory factors in Hashimoto's thyroid.
1. Introduction
Hashimoto's thyroiditis, also known as chronic lymphocytic or autoimmune thyroiditis, is an autoimmune thyroid disease that causes the immune system to attack and destroy the thyroid gland [1]. It is characterized by an enlarged thyroid gland, parenchymal lymphocytic infiltration, and the presence of thyroid antigen-specific antibodies [2]. Hashimoto's thyroiditis causes chronic inflammation of the thyroid tissue and may result in hypothyroidism in 20–30% of patients [3]. The incidence is approximately 3 to 6 cases per 10,000 people per year, with a prevalence of at least 2% in women. The glands involved in thyroiditis often lose the ability to store iodine, produce and secrete rod proteins that circulate in the plasma, and fail to make hormones efficiently [4,5]. At present, methylprednisolone is often used in clinical practice for Hashimoto's thyroiditis treatment, which could inhibit the synthesis of the thyroid gland and alleviate the patient's clinical symptoms. However, research has shown that the use of methimazole alone in patients with Hashimoto's thyroiditis for long term often have poor prognosis.
Traditional Chinese medicine is remarkably effective in the adjuvant treatment of the disease, especially in improving clinical symptoms, prolonging patient survival, and modulating immune function. As an effective method for preventing and treating diseases, TCM has been increasingly used worldwide in the past decades [6]. Yanghe decoction is a famous formula consisting of Rehmannia, deer horn gum, cinnamon, rue, Ephedra, ginger charcoal, and licorice [7]. It has the effect of warming yang and nourishing blood and dispersing cold and moving stagnation. For centuries, Yang He Tang has been proven to be used to treat a variety of noninfectious inflammatory conditions [8].
Yanghe decoction can be combined with modern therapies, which have a combination of “multicomponent, multitarget, and multipathway” regulatory mechanisms and have fewer toxic side effects [9]. In one study, Yang He Tang was shown to have a high mean cure rate (defined as complete regression or significant improvement of lumps and pain for at least two months) in patients with chronic breast fibrosis and palpable lumps [10]. Fewer studies have clinically investigated the effect of Yanghe decoction in the treatment of Hashimoto's thyroiditis. Therefore, the present study was conducted to investigate the potential mechanism of Yanghe decoction in the treatment of Hashimoto's thyroiditis through a metabolomic approach.
2. Material and Methods
2.1. Animal Grouping and Model Construction
Nine NOD mice (4 weeks old) were purchased from the Nanjing Biomedical Research Institute of Nanjing University. NOD mice were randomly divided into three groups: control group (group C), model group (group M), and drug administration group (group T), with three mice in each group. The mice in the model group and the drug administration group were treated with porcine thyroglobulin and high iodine water to establish the mouse model of autoimmune thyroiditis. After successful modeling, Yanghe decoction formula granule (Xuyang Pharmaceutical Co., LTD., China) was prepared into 0.5 g/mL liquid medicine; the drug-administered group was given 0.5 g/ml Yanghe decoction formula 1 ml/100 g by gavage for 1 h, and the model group and normal group were given the same amount of saline by gavage once a day for 10 weeks. The serum and plasma samples were collected and stored at −20°C for serum and −80°C for plasma. The study protocols were approved by the Institutional Animal Care and Use Committee of Nanjing University of Chinese Medicine Affiliated Yancheng.
2.2. Enzyme-Linked Immunosorbent Assay
The serum collected was assayed for IL-35 (interleukin-35) and IL-6 (interleukin-6) inflammatory factors using enzyme-linked immunosorbent assay (ELISA) kits. The experiment was performed according to the instructions.
2.3. Mass Spectrometry Coupled with Ultra-High Performance Liquid-Phase Detection
Metabolite extraction was performed in strict accordance with the operating instructions, followed by onboard detection.
On-Board Detection. The target compounds were chromatographed on a Waters ACQUITY UPLCBEH Amide (2.1 mm × 100 mm, 1.7 μm) column using a Vanquish (Thermo Fisher Scientific) ultra-performance liquid chromatography. The A phase of the liquid chromatography was aqueous containing 25 mmol/L ammonium acetate and 25 mmol/L ammonia, and the B phase was acetonitrile. The sample tray temperature is 4°C, and injection volume is 2 μL.
The Thermo Q Exactive HFX mass spectrometer was capable of primary and secondary mass spectrometry data acquisition under the control of the control software Xcalibur (Thermo). Detailed parameters were as follows: sheath gas flow rate, 30 Arb; Aux gas flow rate, 25 Arb; capillary temperature: 350°C; full ms resolution, 60000; MS/MS resolution, 7500; collision energy, 10/30/60 in NCE mode; and spray voltage: 3.6 kV (positive) or −3.2 kV (negative).
Data Processing. The raw data were converted to mzXML format by ProteoWizard software, and then the peak identification, peak extraction, peak alignment, and integration were performed using the R package (kernel XCMS) written by ourselves and then matched with the BiotreeDB (V2.1) self-built secondary mass spectrometry database for substance annotation.
2.4. Mass Spectrometry Coupled with Gas Chromatography Detection
Metabolite extraction was performed strictly according to the operating instructions, and then all samples were analyzed by gas chromatography and time-of-flight mass spectrometry.
On-Board Detection. GC-TOF-MS analysis was performed using an Agilent 7890 gas chromatograph and a time-of-flight mass spectrometer. The system used a DB-5MS capillary column. 1 μL aliquots were injected in a nonsplit mode. Helium was used as the carrier gas with a front inlet purge flow rate of 3 mL min−1 and a gas flow rate through the column of 1 ml min−1. The initial temperature was held at 50°C for 1 min, then increased to 310°C at a rate of 20°C, and then held at 310°C for 6 min. The injection, transmission line, and ion source temperatures were 280, 280, and 250°C, respectively. The energy in electron collision mode was −70 eV. After a solvent delay of 4.83 min, mass spectral data were acquired in full-scan mode in the m/z range of 50–500 at a rate of 12.5 spectra per second.
Data Processing. The mass spectral data were analyzed for peak extraction, baseline correction, deconvolution, peak integration, and peak alignment using ChromaTOF software (V 4.3x, LECO). For the substance characterization work, the LECO-Fiehn Rtx5 database was used, including mass spectrometry matching and retention time index matching.
2.5. Nuclear Magnetic Resonance Detection
The experimental testing equipment was Varian Inova 600M Agilent.
Description of the Spectral Processing. The integration interval of the serum NMR spectra was 0.5–8.5 ppm with an integration spacing of 0.002 ppm, and a section of 4.60–4.80 ppm containing the residual water peak and the urea peak at 5.20–5.25 ppm and the region of its influence was removed. Among them, the demonstration of mouse serum spectra for groups C, M, and T were chosen: 1, 9, and 17, respectively.
2.6. Principal Component Analysis (PCA)
Data were formatted for logarithmic (LOG) transformation plus centralization (CTR) using SIMCA software (V16.0.2; Sartorius Stedim Data Analytics AB, Umea, Sweden), followed by automated modeling analysis.
2.7. Orthogonal Partial Least Squares-Discriminant Analysis (OPLS-DA)
The data were UV-formatted using SIMCA software (V14.1; MKS Data Analytics Solutions, Umea, Sweden), and OPLS-DA modeling analysis was first performed on the first principal component, and the quality of the model was tested with 7-fold cross-validation (7-fold cross-validation). Then, R2Y (interpretability of the model for the categorical variable Y) and Q2 (predictability of the model) were used to judge the validity of the model; finally, the validity of the model was further tested by a permutation test, which randomly changed the order of the categorical variable Y several times to obtain different random Q2 values.
2.8. Pathway Enrichment Analysis
The metabolic pathways of differentially expressed metabolites were analyzed by searching the relevant metabolic pathways of differentially expressed metabolites using authoritative metabolite databases such as Kyoto Encyclopedia of Genes and Genomes (KEGG) and PubChem.
3. Results
3.1. Principal Component Analysis
First, we performed PCA on the results of the three assays to observe the overall metabolic levels and species differences between the groups. The results of principal component analysis (positive ions) of the mass spectrometry coupled with gas and high-performance liquid phases showed that the samples of groups M and T were more closely distributed and both groups were distant from the samples of group C. The results of the NMR principal component analysis showed that the samples of groups M and T were distributed more into and partitioned from the samples of group C. This can all indicate that the more similar the type and content of metabolites in groups M and T, the more different the overall metabolic levels in groups M and T from group C. The samples were all in the 95% confidence interval. See Figure 1.
Figure 1.

Principal component analysis. (a) Scatter plot and 3D plot of PCA scores for all samples detected by mass spectrometry coupled with the high-performance liquid phase. (b) Scatter plot and 3D plot of PCA scores for all samples detected by mass spectrometry coupled with the gas phase. (c) Scatter plot and 3D plot of PCA scores of all samples detected by NMR.
3.2. Orthogonal Partial Least Squares-Discriminant Analysis (OPLS-DA) and Differential Metabolite Analysis
We then modeled OPLS-DA for the M and T groups and screened for differential metabolites. The scatter plots of OPLS-DA model scores for the three assays showed that the horizontal distance between samples was farther for group M versus group T, which could indicate the greater the difference between the two groups, and the samples were very clearly differentiated. The samples were all in the 95% confidence interval. The results of the differential metabolite analysis showed that a total of 38 differential metabolites were screened for the mass spectrometry coupled with high-performance liquid phase (Table 1); a total of 120 differential metabolites were screened for the mass spectrometry coupled with gas phase (Table 2), and the conditions for this metabolite screening were VIP value (the projected importance of the variable obtained from the OPLS-DA model for the comparison of the substance in this group) > 1 and P < 0.05. NMR analysis showed that α-glucose and β-glucose were significant differentiating metabolites (see Figure 2).
Table 1.
Differential metabolites detected by mass spectrometry and high-performance liquid chromatography.
| ID | MS2 name | MS2 score | rt | mz | SuperClass | Type | MEAN T | MEAN M | VIP | P-value | Q-value | FOLDCHANGE | LOG_FOLDCHANGE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22 | D-Glutamine | 0.999291 | 389.5485 | 147.0759376 | Organic acids and derivatives | Forward | 3.746183952 | 3.446653347 | 1.931664281 | 0.014765644 | 1 | 1.086904767 | 0.120225539 |
| 47 | Trigonelline | 0.995484 | 301.0875 | 138.0543287 | Alkaloids and derivatives | Forward | 1.024957601 | 0.838952133 | 2.022165048 | 0.046051103 | 1 | 1.221711658 | 0.288903828 |
| 54 | N-Acetylhistamine | 0.994856 | 147.787 | 154.0968957 | Organic acids and derivatives | Forward | 0.073990814 | 0.110698454 | 1.829180635 | 0.025585478 | 1 | 0.668399709 | −0.58121699 |
| 56 | Kanzonol K | 0.994656 | 35.0689 | 437.1927582 | Phenylpropanoids and polyketides | Forward | 0.051954891 | 0.031048015 | 2.101281275 | 0.001974289 | 1 | 1.673372393 | 0.742758539 |
| 69 | L-Methionine | 0.991602 | 301.415 | 150.0577251 | Organic acids and derivatives | Forward | 0.616919645 | 0.468069797 | 1.939910681 | 0.019678144 | 1 | 1.318007803 | 0.398358912 |
| 99 | Ecgonine | 0.981134 | 350.546 | 186.1120848 | Alkaloids and derivatives | Forward | 0.027347509 | 0.030654513 | 1.926689881 | 0.031693069 | 1 | 0.892120183 | −0.164690017 |
| 101 | L-histidine | 0.979726 | 408.5865 | 156.0761942 | Organic acids and derivatives | Forward | 0.49405337 | 0.223894139 | 2.08197046 | 0.008582433 | 1 | 2.206638244 | 1.141850134 |
| 107 | L-phenylalanine | 0.977905 | 275.944 | 166.0854692 | Organic acids and derivatives | Forward | 4.763771466 | 3.828460241 | 1.897216209 | 0.034322892 | 1 | 1.244304803 | 0.315339929 |
| 112 | L-alanine | 0.975801 | 363.879 | 90.05507238 | Organic acids and derivatives | Forward | 0.437920469 | 0.363410363 | 1.912131498 | 0.031994707 | 1 | 1.205030219 | 0.269069326 |
| 138 | Phytosphingosine | 0.965381 | 57.8408 | 318.299383 | Organic nitrogen compounds | forward | 1.743529266 | 1.126406912 | 1.948385533 | 0.021992696 | 1 | 1.547868047 | 0.630282489 |
| 141 | Pentanenitrile | 0.962912 | 266.604 | 84.08082795 | Organonitrogen compounds | Forward | 0.264520137 | 0.226518588 | 2.005800964 | 0.018824486 | 1 | 1.167763487 | 0.223748107 |
| 153 | Imidazoleacetic acid riboside | 0.954489 | 370.1495 | 259.0919389 | Nucleosides, nucleotides, and analogues | Forward | 0.014965502 | 0.019469476 | 2.040287972 | 0.006044593 | 1 | 0.768664826 | −0.379573442 |
| 156 | 3beta,6beta-Dihydroxynortropane | 0.948011 | 52.1612 | 144.1012842 | Alkaloids and derivatives | Forward | 0.118818145 | 0.086495728 | 2.050482112 | 0.004431311 | 1 | 1.373688018 | 0.458054387 |
| 158 | L-kynurenine | 0.944886 | 280.281 | 209.0914398 | Organic oxygen compounds | Forward | 0.10372474 | 0.082802841 | 1.987721923 | 0.013173077 | 1 | 1.252671263 | 0.32500786 |
| 160 | Arecaidine | 0.944798 | 282.167 | 142.0858524 | Alkaloids and derivatives | Forward | 0.080085294 | 0.053014131 | 2.016796656 | 0.022004872 | 1 | 1.510640518 | 0.595160389 |
| 161 | Carnosine | 0.942805 | 434.3945 | 227.113435 | Organic acids and derivatives | Forward | 0.048044936 | 0.066372136 | 1.819056239 | 0.031112771 | 1 | 0.723872074 | −0.466193334 |
| 169 | Thelephoric acid | 0.935613 | 407.237 | 353.0278188 | Organoheterocyclic compounds | Forward | 0.002605381 | 0.003775405 | 1.806140708 | 0.033212017 | 1 | 0.690093214 | −0.535136849 |
| 180 | L-acetylcarnitine | 0.92253 | 320.788 | 204.1225337 | Lipids and lipid-like molecules | Forward | 3.698529842 | 2.839908003 | 1.877147018 | 0.024898946 | 1 | 1.302341427 | 0.381107721 |
| 204 | Alpha-methylstyrene | 0.898642 | 35.2889 | 119.0850948 | Benzenoids | Forward | 0.188441473 | 0.131632093 | 2.159887496 | 0.001577729 | 1 | 1.431576978 | 0.517605248 |
| 228 | Glycerophosphocholine | 0.86945 | 400.206 | 258.1089005 | Lipids and lipid-like molecules | Forward | 0.615951963 | 0.925741511 | 1.864643532 | 0.035821933 | 1 | 0.665360638 | −0.587791573 |
| 230 | 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide | 0.865109 | 171.668 | 257.1128126 | Organic oxygen compounds | Forward | 0.117325608 | 0.138566581 | 2.138035911 | 0.004789509 | 1 | 0.846709269 | −0.240061413 |
| 238 | D-biopterin | 0.853104 | 272.631 | 238.0928999 | Organoheterocyclic compounds | Forward | 0.026486036 | 0.021446249 | 1.82825674 | 0.040439888 | 1 | 1.234996232 | 0.30450664 |
| 240 | N-(3-methylbutyl)acetamide | 0.850798 | 268.9475 | 130.1221116 | Organic acids and derivatives | Forward | 0.058209581 | 0.049743365 | 2.142098263 | 0.000620136 | 1 | 1.170197912 | 0.226752549 |
| 254 | N-acetylornithine | 0.829892 | 374.192 | 175.1070165 | Organic acids and derivatives | Forward | 0.056279893 | 0.047008306 | 1.830587028 | 0.035370672 | 1 | 1.197232943 | 0.259703882 |
| 259 | 1-(Hydroxymethyl)-5,5-dimethyl-2,4-imidazolidinedione | 0.818992 | 407.131 | 159.0757679 | Organoheterocyclic compounds | Forward | 0.182086983 | 0.15583556 | 1.945664927 | 0.014442075 | 1 | 1.168455928 | 0.224603319 |
| 291 | Biochanin A | 0.769766 | 39.59165 | 285.07362 | Phenylpropanoids and polyketides | forward | 0.031721703 | 0.041732531 | 1.920254712 | 0.018257478 | 1 | 0.760119332 | −0.395702167 |
| 295 | Heptadecanoyl carnitine | 0.756939 | 194.733 | 414.3571643 | Lipids and lipid-like molecules | Forward | 0.017403164 | 0.022118651 | 2.137696573 | 0.00072227 | 1 | 0.786809469 | −0.345913775 |
| 315 | 3-[(3-Methylbutyl)nitrosoamino]-2-butanone | 0.715231 | 36.73805 | 187.1434871 | Organooxygen compounds | Forward | 0.339965307 | 0.457120856 | 2.061300025 | 0.008977331 | 1 | 0.743709903 | −0.427188112 |
| 320 | 2-Acetylpyrazine | 0.710279 | 330.908 | 123.0549956 | Organooxygen compounds | Forward | 0.013123324 | 0.008784152 | 1.970470389 | 0.02020786 | 1 | 1.493977369 | 0.579158294 |
| 328 | Sedoheptulose 1-phosphate | 0.700854 | 40.022 | 291.0477486 | Organic oxygen compounds | Forward | 0.051097691 | 0.069345806 | 2.046508406 | 0.007069591 | 1 | 0.736853377 | −0.440550522 |
| 360 | Glechomafuran | 0.646208 | 224.3045 | 231.1407859 | Lipids and lipid-like molecules | Forward | 0.010033971 | 0.014750196 | 2.095991059 | 0.002844627 | 1 | 0.680260196 | −0.55584142 |
| 384 | LysoPC(17 : 0) | 0.611195 | 214.164 | 510.3549507 | Lipids and lipid-like molecules | Forward | 0.772031639 | 1.046868823 | 1.889934534 | 0.045513658 | 1 | 0.73746741 | −0.4393488 |
| 410 | Acetyl-N-formyl-5-methoxykynurenamine | 0.577916 | 24.7427 | 265.1210007 | Organic oxygen compounds | Forward | 0.010452578 | 0.006475994 | 2.18949614 | 9.71037E−05 | 1 | 1.614049998 | 0.690685269 |
| 430 | Cysteinyl-serine | 0.560691 | 25.0757 | 209.0581161 | Organic acids and derivatives | Forward | 0.542806005 | 0.285681699 | 1.941743744 | 0.041010554 | 1 | 1.900037726 | 0.926028064 |
| 435 | L-octanoylcarnitine | 0.556023 | 224.21 | 288.2159451 | Lipids and lipid-like molecules | Forward | 0.064410974 | 0.089677252 | 2.106970841 | 0.002284565 | 1 | 0.718253205 | −0.47743557 |
| 442 | S-methylmethionine | 0.553207 | 336.697 | 164.0731609 | Forward | 0.032573318 | 0.044869274 | 1.846945723 | 0.032907818 | 1 | 0.725960445 | −0.462037152 | |
| 471 | 4-Aminohippuric acid | 0.488799 | 315.061 | 184.0895643 | Benzenoids | Forward | 0.009328513 | 0.023072876 | 1.911670897 | 0.010251036 | 1 | 0.404306452 | −1.306478867 |
| 477 | PE(16 : 0/18 : 3(9Z,12Z,15Z)) | 0.471196 | 164.6285 | 714.5059277 | Lipids and lipid-like molecules | Forward | 0.043175276 | 0.02733873 | 1.838157839 | 0.032662642 | 1 | 1.579271456 | 0.659259173 |
| ID | The unique data number of the substance in this qualitative analysis | ||||||||||||
| MS2 name | The substance name obtained by qualitative matching analysis of secondary mass spectrometry | ||||||||||||
| MS2 score | The score of the second-level match, with the value [0, 1] | ||||||||||||
| rt | Chromatographic retention time of the substance | ||||||||||||
| mz | Material characteristics mass charge ratio of ions | ||||||||||||
| SuperClass | Classification information of the substance in the HMDB database | ||||||||||||
| Type | The matching mode includes MS2 forward/reverse matching (MS2 forward/reverse), first-order average molecular weight/single isotope molecular weight matching and no matching | ||||||||||||
| MEAN OO | The mean of the relative quantitative value of the substance in one of the experimental groups within the group comparison | ||||||||||||
| MEAN XX | The mean of the relative quantitative value of the substance in the other experimental group within the group comparison | ||||||||||||
| VIP | The substance in the group was compared to the OPLS-DA model obtained by the variable projection significance | ||||||||||||
| P-value | The p-value obtained by the t-test of this substance in the group comparison, p-value = probabilityof hypothesis being correct but rejected = number of negative results/total number of results, is a test probability against the sample data | ||||||||||||
| Q-value | The hypothesis test statistic (p-value) is the result after the correction of multiple hypothesis test. Q value = the probability of being rejected but correct = the number of false-positive results/thenumber of presumed positive results. It is a test probability of the inference obtained from statistical test and the re-statistics of p-value | ||||||||||||
| FOLD CHANGE | The substance in this group was compared with the multiple relationship between the two groups of experiments | ||||||||||||
| LOG_FOLDCHANGE | FOLD CHANGE takes the logarithm base 2 | ||||||||||||
Table 2.
Differential metabolites detected by mass spectrometry combined with gas phase.
| ID | Peak2 | Similarity | rt | Count | Mass | MEAN T | MEAN M | VIP | P-value | Q-value | FOLDCHANGE | LOG_FOLDCHANGE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 69 | 2-Hydroxybutanoic acid | 923 | 5.90393,0 | 9 | 131 | 1.272515066 | 1.829157 | 1.299843399 | 0.030824766 | 0.054717746 | 0.695683796 | −0.523496376 |
| 87 | 3-Hydroxybutyric acid | 917 | 6.15207,0 | 9 | 147 | 25.48762597 | 38.1509 | 1.435772881 | 0.006906593 | 0.031058352 | 0.668074026 | −0.581920125 |
| 228 | L-malic acid | 910 | 8.38126,0 | 9 | 73 | 15.02098304 | 24.18815 | 1.206850204 | 0.045844599 | 0.064707169 | 0.621005853 | −0.68732123 |
| 407 | Palmitoleic acid | 903 | 11.4327,0 | 9 | 55 | 4.427715453 | 6.258029 | 1.236645983 | 0.049653209 | 0.067078325 | 0.707525543 | −0.499145861 |
| 410 | Palmitic acid | 878 | 11.5306,0 | 9 | 117 | 20.90998716 | 28.73753 | 1.309850706 | 0.025056075 | 0.05026023 | 0.727619379 | −0.458744127 |
| 68 | Glycine 1 | 876 | 5.88319,0 | 9 | 102 | 3.920530889 | 5.969469 | 1.437149115 | 0.003623146 | 0.031058352 | 0.656763806 | −0.606553473 |
| 144 | glycerol | 855 | 6.94956,0 | 9 | 205 | 14.73609113 | 22.11935 | 1.316507776 | 0.030374647 | 0.054407164 | 0.66620819 | −0.585955005 |
| 234 | Threitol | 852 | 8.47978,0 | 9 | 217 | 0.320598289 | 0.534807 | 1.439750027 | 0.003284907 | 0.031058352 | 0.599465913 | −0.738250374 |
| 273 | Alpha-ketoglutaric acid | 826 | 8.93667,0 | 9 | 73 | 4.392760756 | 7.040861 | 1.19046366 | 0.04958074 | 0.067035106 | 0.623895417 | −0.680623882 |
| 172 | Uracil | 822 | 7.43667,0 | 9 | 241 | 0.382125402 | 0.661469 | 1.353053457 | 0.022060725 | 0.047455437 | 0.577691894 | −0.791627843 |
| 184 | Pelargonic acid | 794 | 7.60111,0 | 9 | 215 | 0.046390864 | 0.07566 | 1.23255862 | 0.043826199 | 0.063362351 | 0.613151594 | −0.705684289 |
| 222 | Aminomalonic acid | 791 | 8.28837,0 | 9 | 218 | 0.413476931 | 0.584889 | 1.244433147 | 0.031388031 | 0.055098631 | 0.706932665 | −0.50035529 |
| 206 | 2-Deoxytetronic acid | 780 | 8.01104,0 | 9 | 73 | 4.287775664 | 6.992805 | 1.380659529 | 0.007758549 | 0.031058352 | 0.613169609 | −0.705641901 |
| 85 | 3-Hydroxypyridine | 778 | 6.0817,0 | 9 | 152 | 0.233075193 | 0.349579 | 1.473437449 | 0.004190223 | 0.031058352 | 0.666731544 | −0.584822111 |
| 127 | 4-Hydroxybutyrate | 769 | 6.69919,0 | 9 | 233 | 0.018386599 | 0.032341 | 1.34064562 | 0.025110742 | 0.050307906 | 0.568527482 | −0.814698006 |
| 427 | heptadecanoic acid | 745 | 11.985,0 | 9 | 117 | 0.110508121 | 0.168502 | 1.336703207 | 0.032082258 | 0.055556587 | 0.655828223 | −0.608610108 |
| 197 | Thymine | 677 | 7.85356,0 | 9 | 270 | 0.043778381 | 0.066104 | 1.371605211 | 0.012906566 | 0.037801216 | 0.662263926 | −0.59452182 |
| 110 | Malonic acid 1 | 674 | 6.46348,0 | 9 | 141 | 0.120153186 | 0.212515 | 1.480974611 | 0.001576369 | 0.031058352 | 0.56538798 | −0.822686883 |
| 99 | Methyl phosphate | 665 | 6.28585,0 | 9 | 241 | 0.115662474 | 0.211687 | 1.463936501 | 0.002727024 | 0.031058352 | 0.5463833 | −0.872014707 |
| 207 | Beta-alanine 2 | 643 | 8.03652,0 | 9 | 248 | 0.054056527 | 0.101364 | 1.421035491 | 0.014950627 | 0.039659996 | 0.533289189 | −0.907010013 |
| 162 | 2,3-Dihydroxypyridine | 633 | 7.28778,0 | 9 | 240 | 0.086432291 | 0.12972 | 1.393394351 | 0.006663844 | 0.031058352 | 0.666297891 | −0.585760767 |
| 463 | N-acetyl-5-hydroxytryptamine 1 | 590 | 13.2097,0 | 9 | 290 | 160.0062516 | 231.7193 | 1.303021085 | 0.041478731 | 0.061714361 | 0.690517501 | −0.534250115 |
| 113 | 3-Aminoisobutyric acid 2 | 520 | 6.51726,0 | 9 | 57 | 0.32200107 | 0.496484 | 1.338967469 | 0.015637714 | 0.04020852 | 0.648562563 | −0.624682345 |
| 307 | 1,2-Cyclohexanedione 4 | 517 | 9.492,0 | 8 | 205 | 0.101748813 | 0.181678 | 1.387571447 | 0.026616559 | 0.051576505 | 0.560051285 | −0.836369152 |
| 216 | Erythrose 1 | 514 | 8.18007,0 | 9 | 350 | 0.689931679 | 1.092036 | 1.272409468 | 0.028301472 | 0.052900868 | 0.631784782 | −0.662494907 |
| 219 | Capric acid | 508 | 8.24689,0 | 9 | 117 | 0.161212023 | 0.274597 | 1.358543235 | 0.010727066 | 0.035339822 | 0.587086555 | −0.768354878 |
| 146 | 2-Deoxyuridine | 503 | 7.01356,0 | 3 | 81 | 0.000258002 | 0.659853 | 1.539040505 | 0.016123039 | 0.040576096 | 0.000390999 | −11.32054852 |
| 377 | D-altrose 2 | 487 | 10.8282,0 | 3 | 257 | 0.000258002 | 0.138383 | 1.541803731 | 0.000279156 | 0.031058352 | 0.0018644 | −9.067072758 |
| 111 | Methylmalonic acid | 481 | 6.46941,0 | 9 | 226 | 0.210469269 | 0.423913 | 1.496235451 | 0.002203188 | 0.031058352 | 0.496491996 | −1.010157634 |
| 285 | Digitoxose 1 | 452 | 9.08156,0 | 3 | 73 | 0.000258002 | 0.000388 | 1.382297717 | 0.007898488 | 0.031058352 | 0.664566179 | −0.589515221 |
| 246 | trans-4-Hydroxy-L-proline 2 | 449 | 8.64244,0 | 3 | 186 | 0.000258002 | 0.000388 | 1.382297717 | 0.007898488 | 0.031058352 | 0.664566179 | −0.589515221 |
| 88 | Sulfuric acid | 419 | 6.16896,0 | 9 | 281 | 0.759582216 | 1.140343 | 1.321189491 | 0.030078726 | 0.054199895 | 0.666099824 | −0.586189695 |
| 218 | 2,4-Diaminobutyric acid 3 | 416 | 8.2337,0 | 9 | 103 | 0.177346978 | 0.279941 | 1.370608087 | 0.009107719 | 0.033074562 | 0.633516577 | −0.658545725 |
| 425 | d-Glucoheptose 1 | 412 | 11.9031,0 | 7 | 319 | 0.012258146 | 0.021077 | 1.315429516 | 0.039316399 | 0.060377704 | 0.581574962 | −0.781962934 |
| 501 | Isomaltose 2 | 410 | 15.118,0 | 7 | 73 | 0.21680148 | 0.330811 | 1.462708603 | 0.005347921 | 0.031058352 | 0.655363457 | −0.609632863 |
| 211 | N-acetyl-L-leucine 2 | 406 | 8.12433,0 | 8 | 86 | 0.058678762 | 0.087162 | 1.447579125 | 0.011125631 | 0.035834826 | 0.673218373 | −0.570853545 |
| 309 | L-homoserine 3 | 396 | 9.52289,0 | 6 | 290 | 0.052160115 | 0.075824 | 1.481796159 | 0.00209498 | 0.031058352 | 0.687909761 | −0.539708769 |
| 77 | 2-Ketovaleric acid 2 | 393 | 5.97089,0 | 9 | 89 | 0.148017445 | 0.248358 | 1.44720369 | 0.004315057 | 0.031058352 | 0.595983832 | −0.746654902 |
| 238 | 4-Acetamidobutyric acid 2 | 387 | 8.55919,0 | 9 | 174 | 0.262681494 | 0.414491 | 1.304395218 | 0.023923344 | 0.049245254 | 0.633744092 | −0.658027703 |
| 343 | Biuret 2 | 385 | 10.0571,0 | 6 | 171 | 0.131112438 | 0.11193 | 1.298491114 | 0.038783781 | 0.060035166 | 1.171379459 | 0.228208501 |
| 149 | O-acetylserine 2 | 384 | 7.08467,0 | 3 | 116 | 0.000258002 | 0.000388 | 1.382297717 | 0.007898488 | 0.031058352 | 0.664566179 | −0.589515221 |
| 170 | Oxamide | 382 | 7.37756,0 | 9 | 116 | 0.638063028 | 0.963743 | 1.375059784 | 0.010946865 | 0.035615566 | 0.66206751 | −0.594949762 |
| 193 | Resorcinol | 364 | 7.74837,0 | 9 | 240 | 0.1893703 | 0.270561 | 1.422135343 | 0.028840031 | 0.053304636 | 0.699917794 | −0.514742608 |
| 34 | 2-Ketobutyric acid 2 | 359 | 5.37696,0 | 9 | 174 | 3.895398713 | 6.310969 | 1.452753771 | 0.003819666 | 0.031058352 | 0.617242587 | −0.69609049 |
| 495 | Maltose | 344 | 14.4673,0 | 3 | 204 | 0.000258002 | 0.000388 | 1.382297717 | 0.007898488 | 0.031058352 | 0.664566179 | −0.589515221 |
| 506 | Ergosterol | 339 | 17.6037,0 | 7 | 129 | 0.038142477 | 0.170062 | 1.152056064 | 0.040476247 | 0.061105175 | 0.224285234 | −2.156593449 |
| 290 | D-erythronolactone 2 | 338 | 9.18748,0 | 9 | 244 | 0.233520567 | 0.335404 | 1.338741737 | 0.015238113 | 0.03989368 | 0.696237385 | −0.522348811 |
| 417 | Sinapyl alcohol 1 | 331 | 11.7691,0 | 3 | 241 | 0.000258002 | 0.000388 | 1.382297717 | 0.007898488 | 0.031058352 | 0.664566179 | −0.589515221 |
| 416 | N-acetyl-D-galactosamine 1 | 329 | 11.7478,0 | 3 | 202 | 0.000258002 | 0.000388 | 1.382297717 | 0.007898488 | 0.031058352 | 0.664566179 | −0.589515221 |
| 114 | 3-Methylamino-1,2-propanediol 1 | 327 | 6.52733,0 | 9 | 116 | 0.145928713 | 0.251951 | 1.487710076 | 0.000575224 | 0.031058352 | 0.579194579 | −0.787879996 |
| 92 | 4-Hydroxypyridine | 326 | 6.20052,0 | 9 | 141 | 0.489927793 | 0.795927 | 1.451323971 | 0.002465951 | 0.031058352 | 0.615543839 | −0.700066486 |
| 251 | Cytosine | 322 | 8.68941,0 | 9 | 314 | 2.509840552 | 4.082056 | 1.283159978 | 0.021963317 | 0.047357392 | 0.614847194 | −0.701700187 |
| 507 | Cholestane-3,5,6-triol, (3?5?6?- | 321 | 18.7661,0 | 9 | 57 | 0.885146653 | 2.002186 | 1.387564892 | 0.006905578 | 0.031058352 | 0.442090187 | −1.177587384 |
| 295 | 2-Carboxybenzaldehyde | 318 | 9.29889,0 | 3 | 448 | 0.000258002 | 0.040566 | 1.54194144 | 0.001888566 | 0.031058352 | 0.006360115 | −7.296731326 |
| 486 | Alizarin | 296 | 13.9349,0 | 3 | 192 | 0.000258002 | 0.000388 | 1.382297717 | 0.007898488 | 0.031058352 | 0.664566179 | −0.589515221 |
| 255 | Maleamate 2 | 272 | 8.72638,0 | 7 | 244 | 0.017984542 | 0.083238 | 1.133918922 | 0.023097427 | 0.048471018 | 0.216061427 | −2.210486564 |
| 169 | 4-Acetylbutyric acid 2 | 265 | 7.37059,0 | 9 | 71 | 0.880439414 | 1.444854 | 1.436770641 | 0.018764895 | 0.043859407 | 0.60936233 | −0.714627777 |
| 1 | Analyte 1 | 0 | 4.85415,0 | 9 | 220 | 0.143627588 | 0.206994 | 1.412512528 | 0.009375416 | 0.03347991 | 0.693874841 | −0.527252637 |
| 2 | Analyte 2 | 0 | 4.86659,0 | 9 | 221 | 0.939179789 | 1.482562 | 1.223187422 | 0.048539846 | 0.066406466 | 0.633484237 | −0.658619373 |
| 4 | Analyte 4 | 0 | 4.906,0 | 9 | 127 | 25.04838891 | 40.41622 | 1.427277713 | 0.024022642 | 0.049336351 | 0.619760853 | −0.690216464 |
| 9 | Analyte 9 | 0 | 4.95133,0 | 9 | 56 | 0.076008724 | 0.130549 | 1.387105878 | 0.006481408 | 0.031058352 | 0.582225673 | −0.780349639 |
| 13 | Analyte 13 | 0 | 5.01281,0 | 9 | 281 | 0.519158543 | 0.88159 | 1.415956277 | 0.00432766 | 0.031058352 | 0.588888971 | −0.763932441 |
| 14 | Analyte 15 | 0 | 5.05415,0 | 9 | 89 | 0.126686366 | 0.194385 | 1.370732385 | 0.011314269 | 0.036061485 | 0.651727984 | −0.617658153 |
| 15 | Analyte 16 | 0 | 5.06096,0 | 9 | 71 | 0.14247583 | 0.254596 | 1.382415691 | 0.025128313 | 0.050323204 | 0.559614273 | −0.837495336 |
| 16 | Analyte 17 | 0 | 5.10467,0 | 9 | 248 | 0.189236239 | 0.277412 | 1.185862123 | 0.046349455 | 0.065033621 | 0.682149873 | −0.551839351 |
| 17 | Analyte 18 | 0 | 5.1217,0 | 9 | 71 | 0.23537597 | 0.369089 | 1.285237347 | 0.028223069 | 0.052841325 | 0.63772183 | −0.649000828 |
| 21 | Analyte 22 | 0 | 5.17593,0 | 9 | 160 | 0.117336438 | 0.227376 | 1.396764148 | 0.014713146 | 0.039462234 | 0.516045471 | −0.954429902 |
| 26 | Analyte 27 | 0 | 5.21607,0 | 9 | 207 | 1.534123014 | 2.442395 | 1.406790033 | 0.005116932 | 0.031058352 | 0.628122392 | −0.670882394 |
| 28 | Analyte 29 | 0 | 5.28378,0 | 9 | 318 | 0.490583082 | 0.81612 | 1.436795045 | 0.003319147 | 0.031058352 | 0.601116114 | −0.7342844 |
| 29 | Analyte 30 | 0 | 5.28985,0 | 9 | 141 | 0.424192495 | 0.699525 | 1.423841019 | 0.023362325 | 0.048722604 | 0.606400455 | −0.72165726 |
| 31 | Analyte 32 | 0 | 5.306,0 | 9 | 82 | 0.113890123 | 0.158043 | 1.300767064 | 0.041070167 | 0.061468223 | 0.720626315 | −0.472676759 |
| 35 | Analyte 36 | 0 | 5.38238,0 | 7 | 265 | 0.096659841 | 0.140997 | 1.323588558 | 0.026344832 | 0.051353772 | 0.685547745 | −0.544670949 |
| 42 | Analyte 43 | 0 | 5.50956,0 | 6 | 318 | 0.053147962 | 0.116636 | 1.389043774 | 0.004972626 | 0.031058352 | 0.45567417 | −1.133925502 |
| 43 | Analyte 44 | 0 | 5.53119,0 | 9 | 83 | 1.092646683 | 1.899617 | 1.374864683 | 0.014404096 | 0.039198218 | 0.575193161 | −0.797881572 |
| 45 | Analyte 46 | 0 | 5.57133,0 | 9 | 173 | 0.040681195 | 0.061956 | 1.280531443 | 0.032539528 | 0.055851534 | 0.656616292 | −0.606877547 |
| 53 | Analyte 54 | 0 | 5.69844,0 | 3 | 72 | 0.000258002 | 0.000388 | 1.382297717 | 0.007898488 | 0.031058352 | 0.664566179 | −0.589515221 |
| 60 | Analyte 61 | 0 | 5.77652,0 | 9 | 187 | 0.411739097 | 0.640732 | 1.381876488 | 0.034261264 | 0.056916913 | 0.642607665 | −0.637989906 |
| 61 | Analyte 62 | 0 | 5.78067,0 | 9 | 89 | 0.196207665 | 0.280779 | 1.249714074 | 0.032407158 | 0.055766689 | 0.698796716 | −0.517055267 |
| 65 | Analyte 66 | 0 | 5.85193,0 | 9 | 258 | 1.102739869 | 1.898571 | 1.45940324 | 0.002841114 | 0.031058352 | 0.58082638 | −0.783821116 |
| 66 | Analyte 67 | 0 | 5.86748,0 | 9 | 245 | 0.75141187 | 1.042003 | 1.340855538 | 0.014720908 | 0.039468767 | 0.721122764 | −0.471683209 |
| 70 | Analyte 71 | 0 | 5.91167,0 | 8 | 83 | 0.124600132 | 0.21066 | 1.460188 | 0.005923432 | 0.031058352 | 0.5914747 | −0.757611636 |
| 71 | Analyte 72 | 0 | 5.917,0 | 8 | 206 | 0.109884171 | 0.15268 | 1.26573403 | 0.041287114 | 0.061599284 | 0.719702949 | −0.474526526 |
| 79 | Analyte 80 | 0 | 5.97948,0 | 9 | 130 | 0.06545618 | 0.103826 | 1.457571818 | 0.002601319 | 0.031058352 | 0.630443919 | −0.665560052 |
| 83 | Analyte 84 | 0 | 6.06822,0 | 9 | 89 | 0.629883615 | 0.857153 | 1.348964908 | 0.02146227 | 0.046845666 | 0.734855621 | −0.444467266 |
| 86 | Analyte 87 | 0 | 6.1057,0 | 9 | 355 | 0.013100601 | 0.023343 | 1.464859492 | 0.002920262 | 0.031058352 | 0.561219926 | −0.833361863 |
| 94 | Analyte 95 | 0 | 6.23356,0 | 9 | 322 | 0.091050422 | 0.141299 | 1.335935817 | 0.013050372 | 0.037944549 | 0.644383212 | −0.634009188 |
| 96 | Analyte 97 | 0 | 6.25607,0 | 9 | 221 | 0.273334486 | 0.505144 | 1.382718281 | 0.018461158 | 0.043496426 | 0.541101922 | −0.88602773 |
| 97 | Analyte 98 | 0 | 6.26304,0 | 9 | 267 | 0.052183801 | 0.081353 | 1.339044648 | 0.021887851 | 0.047281114 | 0.641446738 | −0.640598617 |
| 98 | Analyte 99 | 0 | 6.28007,0 | 9 | 152 | 1.243281284 | 1.731247 | 1.362450345 | 0.018110888 | 0.04307052 | 0.718142143 | −0.477658667 |
| 100 | Analyte 101 | 0 | 6.35356,0 | 9 | 211 | 0.149975112 | 0.243234 | 1.269434425 | 0.034442556 | 0.057025121 | 0.6165884 | −0.697620347 |
| 101 | Analyte 102 | 0 | 6.37207,0 | 9 | 221 | 0.126068615 | 0.229719 | 1.369812092 | 0.014918915 | 0.039633839 | 0.548793895 | −0.865663663 |
| 112 | Analyte 114 | 0 | 6.51,0 | 3 | 207 | 0.000258002 | 0.000388 | 1.382297717 | 0.007898488 | 0.031058352 | 0.664566179 | −0.589515221 |
| 124 | Analyte 126 | 0 | 6.667,0 | 4 | 159 | 0.005980118 | 0.035398 | 1.206743852 | 0.007595819 | 0.031058352 | 0.168941731 | −2.565402355 |
| 132 | Analyte 134 | 0 | 6.76096,0 | 9 | 102 | 0.087156126 | 0.13135 | 1.424413383 | 0.004694475 | 0.031058352 | 0.663543315 | −0.591737451 |
| 135 | Analyte 137 | 0 | 6.83089,0 | 9 | 108 | 0.197475333 | 0.322281 | 1.394014594 | 0.009483719 | 0.033640096 | 0.612743258 | −0.70664539 |
| 138 | Analyte 140 | 0 | 6.86778,0 | 9 | 319 | 1.873157639 | 3.114122 | 1.418362299 | 0.007847303 | 0.031058352 | 0.601504164 | −0.73335337 |
| 147 | Analyte 149 | 0 | 7.02956,0 | 9 | 299 | 230.5117654 | 328.7347 | 1.368501132 | 0.014450612 | 0.039238447 | 0.70120909 | −0.512083397 |
| 150 | Analyte 152 | 0 | 7.08911,0 | 3 | 108 | 0.000258002 | 0.000388 | 1.382297717 | 0.007898488 | 0.031058352 | 0.664566179 | −0.589515221 |
| 168 | Analyte 170 | 0 | 7.36319,0 | 9 | 221 | 0.038675613 | 0.064306 | 1.425299204 | 0.003779737 | 0.031058352 | 0.601426746 | −0.733539068 |
| 174 | Analyte 176 | 0 | 7.44822,0 | 3 | 174 | 0.000258002 | 0.000388 | 1.382297717 | 0.007898488 | 0.031058352 | 0.664566179 | −0.589515221 |
| 176 | Analyte 178 | 0 | 7.4663,0 | 9 | 300 | 0.14066929 | 0.25431 | 1.397799484 | 0.009390264 | 0.033501999 | 0.553141309 | −0.854280007 |
| 183 | Analyte 185 | 0 | 7.57178,0 | 9 | 241 | 0.034659852 | 0.05353 | 1.278909492 | 0.022639121 | 0.048028239 | 0.647485316 | −0.62708062 |
| 188 | Analyte 190 | 0 | 7.65457,0 | 7 | 152 | 0.007184055 | 0.027339 | 1.117506783 | 0.048028223 | 0.066091974 | 0.262776377 | −1.92809251 |
| 210 | Analyte 212 | 0 | 8.07785,0 | 9 | 327 | 0.058009466 | 0.101589 | 1.381321063 | 0.008796901 | 0.032586355 | 0.571020535 | −0.808385465 |
| 213 | Analyte 215 | 0 | 8.15637,0 | 9 | 302 | 0.064257101 | 0.098722 | 1.246277713 | 0.028098654 | 0.052746433 | 0.650889175 | −0.619516174 |
| 215 | Analyte 217 | 0 | 8.16556,0 | 9 | 281 | 0.039345122 | 0.080491 | 1.374905261 | 0.003686217 | 0.031058352 | 0.48881664 | −1.032634697 |
| 227 | Analyte 229 | 0 | 8.36156,0 | 9 | 341 | 0.052448759 | 0.086946 | 1.325218816 | 0.017092886 | 0.041786174 | 0.603232561 | −0.72921379 |
| 229 | Analyte 231 | 0 | 8.40367,0 | 8 | 100 | 0.203180031 | 0.32939 | 1.341979958 | 0.013693148 | 0.038560536 | 0.616837794 | −0.697036932 |
| 237 | Analyte 240 | 0 | 8.54081,0 | 9 | 337 | 0.25036522 | 0.455655 | 1.366777246 | 0.036832395 | 0.058732065 | 0.549461995 | −0.863908397 |
| 253 | Analyte 256 | 0 | 8.70644,0 | 9 | 292 | 0.357528929 | 0.515931 | 1.21938121 | 0.048453083 | 0.066353391 | 0.692978537 | −0.529117425 |
| 256 | Analyte 259 | 0 | 8.74333,0 | 8 | 245 | 0.048845708 | 0.090829 | 1.326629434 | 0.009723922 | 0.033987829 | 0.537777275 | −0.894919303 |
| 259 | Analyte 262 | 0 | 8.78319,0 | 9 | 263 | 0.13088251 | 0.231069 | 1.344860566 | 0.044434442 | 0.063774445 | 0.566422421 | −0.820049721 |
| 267 | Analyte 270 | 0 | 8.88467,0 | 9 | 71 | 0.11227297 | 0.204138 | 1.433063266 | 0.00608667 | 0.031058352 | 0.549984911 | −0.862536055 |
| 345 | Analyte 350 | 0 | 10.0673,0 | 5 | 292 | 0.000258002 | 0.063722 | 1.539628212 | 0.004952684 | 0.031058352 | 0.004048846 | −7.948273624 |
| 364 | Analyte 369 | 0 | 10.4758,0 | 3 | 55 | 0.000258002 | 0.063552 | 1.542224923 | 0.016254112 | 0.040672706 | 0.004059669 | −7.944422022 |
| 393 | Analyte 400 | 0 | 11.1802,0 | 6 | 217 | 0.061713649 | 0.161587 | 1.405655109 | 0.013522845 | 0.038401138 | 0.38192255 | −1.38864799 |
| 435 | Analyte 442 | 0 | 12.219,0 | 4 | 67 | 0.005692675 | 0.030499 | 1.184497207 | 0.039424771 | 0.060446736 | 0.186653558 | −2.421565088 |
| 455 | Analyte 463 | 0 | 12.8955,0 | 9 | 232 | 3.442379815 | 4.609231 | 1.359547429 | 0.025385868 | 0.050546071 | 0.746844736 | −0.421119747 |
| 487 | Analyte 495 | 0 | 13.9389,0 | 6 | 259 | 0.013690852 | 0.027019 | 1.401570503 | 0.023138199 | 0.048509945 | 0.506703381 | −0.98078664 |
| 503 | Analyte 511 | 0 | 15.8464,0 | 9 | 357 | 0.080572597 | 0.145165 | 1.270859236 | 0.035617861 | 0.057880623 | 0.555041297 | −0.849332977 |
| ID | The unique data number of the substance in this qualitative analysis | |||||||||||
| Peak | The name of the substance obtained by qualitative analysis | |||||||||||
| Similarity | The matching degree between the substance and the substance in the standard library in qualitative analysis, and the value is [0, 1000] | |||||||||||
| rt | Chromatographic retention time of the substance | |||||||||||
| Count | The number of times the substance was detected in all experimental groups | |||||||||||
| Mass | Material characteristics Mass charge ratio of ions | |||||||||||
| MEAN OO | The mean of the relative quantitative value of the substance in one of the experimental groups within the group comparison | |||||||||||
| MEAN XX | The mean of the relative quantitative value of the substance in the other experimental group within the group comparison | |||||||||||
| VIP | The substance in the group was compared to the OPLS-DAmodel obtained by the variable projection significance | |||||||||||
| P-value | The p-value obtained by the t-test of this substance in the group comparison, p-value = probability of hypothesis being correct but rejected = number of negative results/total number of results, is a test probability against the sample data | |||||||||||
| Q-value | The hypothesis test statistic (p-value) is the result after the correction of multiple hypothesis test. Q-value = the probability of being rejected but correct = the number of false-positive results/the number of presumed positive results. It is a test probability of the inference obtained from statistical test and the re-statistics of p-value | |||||||||||
| FOLD CHANGE | The substance in this group was compared with the multiple relationship between the two groups of experiments | |||||||||||
| LOG_FOLDCHANGE | FOLD CHANGE takes the logarithm base 2 | |||||||||||
Figure 2.

OPLS-DA model score scatter plot and differential metabolite analysis. (a) Scatter plot of OPLS-DA model score and volcano plot of differential metabolites for group M versus group T detected by mass spectrometry coupled with the high-performance liquid phase. (b) Scatter plot of OPLS-DA model score and volcano plot of differential metabolites for group M versus group T detected by mass spectrometry coupled with gas phase. The size of scattering in the volcano plot represents the VIP value of OPLS-DA model, the larger the scatter the larger the VIP value. Significantly upregulated metabolites are shown in red, significantly down-regulated metabolites are shown in blue, and nonsignificantly different metabolites are shown in gray. (c) Scatter plot of OPLS-DA model scores for group M versus group T detected by NMR. (d) OPLS-DA loadings plot for group M versus group (T). The horizontal coordinates in the plot indicate the magnitude of chemical shifts, from right to left, with increasing values of chemical shifts; the vertical coordinates indicate the magnitude of loadings after back conversion, where the shades of color indicate the magnitude of correlation coefficients, red indicates a positive correlation, and blue indicates negative correlation. The marked substances in the figure are the differential metabolites that passed the critical value test of the correlation coefficient.
3.3. Enrichment Analysis of Metabolic Pathways of Differential Metabolites
We further analyzed the effect of differential metabolites on their pathways. The analysis based on the mass spectrometry combined with high-performance liquid phase detection results showed that the differential metabolites in the M and T groups were enriched to 11 pathways (Table 3), among which the pathways with higher enrichment were histidine metabolism, amino acid tRNA biosynthesis, phenylalanine, tyrosine and tryptophan biosynthesis, tryptophan metabolism, phenylalanine metabolism, cysteine, and methionine metabolism. The analysis based on the results of mass spectrometry combined with gas-phase detection showed that the differential metabolites of the M and T groups were enriched to 28 pathways (Table 4), among which the pathways with higher enrichment were pyrimidine metabolism, biosynthesis of pantothenic acid and CoA, metabolism of β-alanine, sulfur metabolism, glycerolipid metabolism, and metabolism of glycine, serine, and threonine. Subsequently, we took the intersection of the pathways enriched by the differential metabolites in the M and T groups for both high-performance liquid- and gas-phase methods coupled to mass spectrometry and obtained a total of five common pathways (biosynthesis of amino acid tRNA, metabolism of D-glutamine and D-glutamate, metabolism of tryptophan, metabolism of nitrogen, and metabolism of arginine and proline). See Figure 3
Table 3.
Enrichment analysis results based on mass spectrometry combined with HPLC.
| Pathway | Total | Hits | Raw p | −ln (p) | Holm adjust | FDR | Impact | Hits cpd | Total cpd |
|---|---|---|---|---|---|---|---|---|---|
| Histidinemetabolism | 15 | 2 | 0.011526 | 4.4632 | 0.95 | 0.94512 | 0.24194 | L-Histidine cpd:C00135; carnosine cpd: C00386 | L-glutamic acid cpd: C00025; 4-imidazolone-5-propionic acid cpd: C03680; urocanic acid cpd: C00785; L-histidine cpd: C00135; imidazole-4-acetaldehyde cpd: C05130; 1-methylhistamine cpd: C05127; methylimidazole acetaldehyde cpd: C05827; histamine cpd: C00388; carnosine cpd: C00386; N-formyl-L-aspartate cpd: C01044; formiminoglutamic acid cpd: C00439; imidazoleacetic acid cpd: C02835; methylimidazoleacetic acid cpd: C05828; L-aspartic acid cpd: C00049; 1-methylhistidine cpd: C01152 |
| Aminoacyl-tRNA biosynthesis | 69 | 3 | 0.039232 | 3.2383 | 1 | 1 | 0 | L-histidine cpd: C00135; L-phenylalanine cpd: C00079; L-methionine cpd: C00073 | L-asparagine cpd: C00152; tRNA(Asn) cpd: C01637; L-histidine cpd: C00135; tRNA(His) cpd: C01643; L-phenylalanine cpd: C00079; tRNA(Phe) cpd: C01648; L-arginine cpd: C00062; tRNA(Arg) cpd: C01636; L-glutamine cpd: C00064; tRNA(Gln) cpd: C01640; L-cysteine cpd: C00097; tRNA(Cys) cpd: C01639; glycine cpd: C00037; tRNA(Gly) cpd: C01642; tRNA(Asp) cpd: C01638; L-aspartic acid cpd: C00049; L-serine cpd: C00065; tRNA(Ser) cpd: C01650; L-methionine cpd: C00073; tRNA(Met) cpd: C01647; L-valine cpd: C00183; tRNA(Val) cpd: C01653; L-alanine cpd: C00041; tRNA(Ala) cpd: C01635; L-lysine cpd: C00047; tRNA(Lys) cpd: C01646; L-isoleucine cpd: C00407; tRNA(Ile) cpd: C01644; tRNA(Leu) cpd: C01645; L-leucine cpd: C00123; L-threonine cpd: C00188; tRNA(Thr) cpd: C01651; tRNA(Trp) cpd: C01652; L-tryptophan cpd: C00078; N10-formyl-thf cpd: C00234; L-methionyl-tRNA cpd: C02430; L-tyrosine cpd: C00082; tRNA(Tyr) cpd: C00787; L-proline cpd: C00148; tRNA(Pro) cpd: C01649; L-glutamic acid cpd: C00025; tRNA(Glu) cpd: C01641; glutaminyl-tRNA cpd: C02282; L-asparaginyl-tRNA(Asn) cpd: C03402; tRNA(Sec) cpd: C16636; L-seryl-tRNA(Sec) cpd: C06481; O-phosphoseryl-tRNA(Sec) cpd: C16638; L-histidyl-tRNA(His) cpd: C02988; L-phenylalanyl-tRNA(Phe) cpd: C03511; L-arginyl-tRNA(Arg) cpd: C02163; L-cysteinyl-tRNA(Cys) cpd: C03125; glycyl-tRNA(Gly) cpd: C02412; L-aspartyl-tRNA(Asp) cpd: C02984; L-seryl-tRNA(Ser) cpd: C02553; L-valyl-tRNA(Val) cpd: C02554; L-alanyl-tRNA cpd: C00886; L-lysyl-tRNA cpd: C01931; L-isoleucyl-tRNA(Ile) cpd: C03127; L-leucyl-tRNA cpd: C02047; L-threonyl-tRNA(Thr) cpd: C02992; L-tryptophanyl-tRNA(Trp) cpd: C03512; tetrahydrofolic acid cpd: C00101; N-formylmethionyl-tRNA cpd: C03294; L-tyrosyl-tRNA(Tyr) cpd: C02839; L-prolyl-tRNA(Pro) cpd: C02702; L-glutamyl-tRNA(Glu) cpd: C02987; L-glutamyl-tRNA(Gln) cpd: C06112; L-aspartyl-tRNA(Asn) cpd: C06113; L-selenocysteinyl-tRNA(Sec) cpd: C06482 |
| Phenylalanine, tyrosine, and tryptophan biosynthesis | 4 | 1 | 0.044453 | 3.1133 | 1 | 1 | 0.5 | L-phenylalanine cpd: C00079 | Phenylpyruvic acid cpd: C00166; L-phenylalanine cpd: C00079; L-tyrosine cpd: C00082; 4-hydroxyphenylpyruvic acid cpd: C01179 |
| D-glutamine and D-glutamate metabolism | 5 | 1 | 0.055273 | 2.8955 | 1 | 1 | 0 | D-glutamine cpd: C00819 | L-glutamic acid cpd: C00025; D-glutamine cpd: C00819; L-glutamine cpd: C00064; oxoglutaric acid cpd: C00026; D-glutamic acid cpd: C00217 |
| Tryptophan metabolism | 40 | 2 | 0.072666 | 2.6219 | 1 | 1 | 0.10987 | L-kynurenine cpd: C00328; acetyl-N-formyl-5-methoxykynurenamine cpd: C05642 | L-tryptophan cpd: C00078; melatonin cpd: C01598; serotonin cpd: C00780; 5-hydroxykynurenamine cpd: C05638; 5-hydroxykynurenine cpd: C05651; 5-hydroxy-L-tryptophan cpd: C00643; L-formylkynurenine cpd: C02700; acetoacetyl-CoA cpd: C00332; (S)-3-hydroxybutanoyl-CoA cpd: C01144; crotonoyl-CoA cpd: C00877; glutaryl-CoA cpd: C00527; oxoadipic acid cpd: C00322; 2-amino-3-carboxymuconic acid semialdehyde cpd: C04409; 3-hydroxyanthranilic acid cpd: C00632; L-kynurenine cpd: C00328; formylanthranilic acid cpd: C05653; L-3-hydroxykynurenine cpd: C03227; 3-hydroxykynurenamine cpd: C05636; indoleacetaldehyde cpd: C00637; 5-hydroxy-N-formylkynurenine cpd: C05648; 5-hydroxyindoleacetaldehyde cpd: C05634; tryptamine cpd: C00398; indoleacrylic acid cpd: C00331; acetyl-N-formyl-5-methoxykynurenamine cpd: C05642; 6-hydroxymelatonin cpd: C05643; N-acetylserotonin cpd: C00978; formyl-5-hydroxykynurenamine cpd: C05647; 4,6-dihydroxyquinoline cpd: C05639; acetyl-CoA cpd: C00024; 2-aminomuconic acid semialdehyde cpd: C03824; 2-aminobenzoic acid cpd: C00108; L-tryptophanyl-tRNA(Trp) cpd: C03512; cinnavalininate cpd: C05640; 4-(2-amino-3-hydroxyphenyl)-2,4-dioxobutanoic acid cpd: C05645; 4-(2-aminophenyl)-2,4-dioxobutanoic acid cpd: C01252; 4,8-dihydroxyquinoline cpd: C05637; indoleacetic acid cpd: C00954; 5-hydroxyindoleacetic acid cpd: C05635; N-methylserotonin cpd: C06212; N-methyltryptamine cpd: C06213 |
| Nitrogen metabolism | 9 | 1 | 0.097415 | 2.3288 | 1 | 1 | 0 | L-histidine cpd: C00135 | Ammonia cpd: C00014; carbon dioxide cpd: C00011; L-glutamic acid cpd: C00025; L-Glutamine cpd: C00064; L-cystathionine cpd: C02291; L-Histidine cpd: C00135; carbamoylphosphate cpd: C00169; carbonic acid cpd: C01353; glycine cpd: C00037 |
| Phenylalanine metabolism | 11 | 1 | 0.11782 | 2.1386 | 1 | 1 | 0.40741 | L-phenylalanine cpd: C00079 | Phenylacetaldehyde cpd: C00601; phenylacetyl-CoA cpd: C00582; L-phenylalanine cpd: C00079; phenylethylamine cpd: C05332; phenylpyruvic acid cpd: C00166; phenylacetic acid cpd: C07086; phenylacetylglycine cpd: C05598; ortho-hydroxyphenylacetic acid cpd: C05852; enol-phenylpyruvate cpd: C02763; 2-phenylacetamide cpd: C02505; L-tyrosine cpd: C00082 |
| Sphingolipid metabolism | 21 | 1 | 0.21351 | 1.5441 | 1 | 1 | 0 | Phytosphingosine cpd: C12144 | Sphinganine cpd: C00836; ceramide 1-phosphate cpd: C02960; sphingosine 1-phosphate cpd: C06124; sphinganine 1-phosphate cpd: C01120; dihydroceramide cpd: C12126; phytoceramide cpd: C12145; SM cpd: C00550; ceramide cpd: C00195; Palmityl-CoA cpd: C00154; L-Serine cpd: C00065; 3-dehydrosphinganine cpd: C02934; galabiosylceramide cpd: C06126; galactosylceramide cpd: C02686; GM4 cpd: C06128; lactosylceramide cpd: C01290; glucosylceramide cpd: C01190; sphingosine cpd: C00319; 3-O-Sulfogalactosylceramide (d18 : : 1/24 : : 0) cpd: C06125; phytosphingosine cpd: C12144; digalactosylceramidesulfate cpd: C06127; O-phosphoethanolamine cpd: C00346 |
| Cysteine and methionine metabolism | 27 | 1 | 0.26616 | 1.3236 | 1 | 1 | 0.08685 | L-methionine cpd: C00073 | 2-Oxo-4-methylthiobutanoic acid cpd: C01180; 1,2-dihydroxy-3-keto-5-methylthiopentene cpd: C15606; 5′-methylthioadenosine cpd: C00170; S-adenosylmethioninamine cpd: C01137; S-adenosylmethionine cpd: C00019; L-cystathionine cpd: C02291; L-homocysteine cpd: C00155; L-serine cpd: C00065; L-methionine cpd: C00073; S-adenosylhomocysteine cpd: C00021; 2,3-diketo-5-methylthiopentyl-1-phosphate cpd: C15650; cysteic acid cpd: C00506; L-cystine cpd: C00491; L-cysteine cpd: C00097; 3-sulfinoalanine cpd: C00606; sulfite cpd: C00094; 3-mercaptopyruvic acid cpd: C00957; 3-methylthiopropionic acid cpd: C08276; 5-methylthioribose 1-phosphate cpd: C04188; 2-ketobutyric acid cpd: C00109; 2-aminoacrylic acid cpd: C02218; 3-sulfopyruvic acid cpd: C05528; thiocysteine cpd: C01962; 3-sulfinylpyruvic acid cpd: C05527; pyruvic acid cpd: C00022; thiosulfate cpd: C00320; 3-mercaptolactic acid cpd: C05823 |
| Glycerophospholipid metabolism | 30 | 1 | 0.29123 | 1.2336 | 1 | 1 | 0.02315 | Glycerophosphocholine cpd: C00670 | Phosphatidylethanolamine cpd: C00350; phosphatidylcholine cpd: C00157; dihydroxyacetone phosphate cpd: C00111; LysoPC (18 : 1(9Z)) cpd: C04230; 1,2-diacyl-sn-glycerol cpd: C00641; citicoline cpd: C00307; phosphorylcholine cpd: C00588; choline cpd: C00114; acetylcholine cpd: C01996; O-phosphoethanolamine cpd: C00346; ethanolamine cpd: C00189; PA (16 : : 0/16 : : 0) cpd: C00416; acyl-CoA cpd: C00040; 1-acyl-sn-glycerol 3-phosphate cpd: C00681; CDP-diacylglycerol cpd: C00269; glycerol 3-phosphate cpd: C00093; 1-acyl-sn-glycero-3-phosphoethanolamine cpd: C04438; 2-acyl-sn-glycero-3-phosphoethanolamine cpd: C05973; 2-acyl-sn-glycero-3-phosphocholine cpd: C04233; CDP-glycerol cpd: C00513; PS (16 : 0/16 : 0) cpd: C02737; phosphatidylglycerol cpd: C00344; dihydroxyacetone phosphate acyl ester cpd: C03372; CDP-ethanolamine cpd: C00570; 1-phosphatidyl-D-myo-inositol cpd: C01194; glycerylphosphorylethanolamine cpd: C01233; glycerophosphocholine cpd: C00670; phosphatidyl-N-methylethanolamine cpd: C01241; phosphatidylglycerophosphate cpd: C03892; cardiolipin cpd: C05980 |
| Arginine and proline metabolism | 44 | 1 | 0.39796 | 0.9214 | 1 | 1 | 0 | N-acetylornithine cpd: C00437 | L-glutamine cpd: C00064; ammonia cpd: C00014; carbamoylphosphate cpd: C00169; ornithine cpd: C00077; citrulline cpd: C00327; L-aspartic acid cpd: C00049; argininosuccinic acid cpd: C03406; L-arginine cpd: C00062; L-glutamic acid cpd: C00025; N-acetylornithine cpd: C00437; L-proline cpd: C00148; peptide cpd: C00012; D-proline cpd: C00763; hydroxyproline cpd: C01157; pyrroline hydroxycarboxylic acid cpd: C04281; L-4-hydroxyglutamate semialdehyde cpd: C05938; L-erythro-4-hydroxyglutamate cpd: C05947; N-(o)-hydroxyarginine cpd: C05933; guanidinoacetic acid cpd: C00581; creatine cpd: C00300; gamma-aminobutyric acid cpd: C00334; agmatine cpd: C00179; L-glutamic-gamma-semialdehyde cpd: C01165; L-glutamic acid 5-phosphate cpd: C03287; (S)-1-pyrroline-5-carboxylate cpd: C03912; putrescine cpd: C00134; 4-aminobutyraldehyde cpd: C00555; S-adenosylmethioninamine cpd: C01137; S-adenosylmethionine cpd: C00019; spermidine cpd: C00315; N-acetylputrescine cpd: C02714; N4-acetylaminobutanal cpd: C05936; cis-4-hydroxy-D-proline cpd: C03440; fumaric acid cpd: C00122; urea cpd: C00086; N-acetyl-L-alanine cpd: C00624; 1-pyrroline-2-carboxylic acid cpd: C03564; D-4-hydroxy-2-oxoglutarate cpd: C05946; nitric oxide cpd: C00533; phosphocreatine cpd: C02305; 4-guanidinobutanoic acid cpd: C01035; spermine cpd: C00750; 4-acetamidobutanoic acid cpd: C02946; 1-pyrroline-4-hydroxy-2-carboxylate cpd: C04282 |
| Pathway | Metabolic pathway name | ||||||||
| Total | The number of metabolites in this pathway | ||||||||
| Hits | The number of differential metabolites hit this pathway | ||||||||
| Raw p | P value of metabolic pathway enrichment analysis | ||||||||
| −ln(p) | Minus log base E of P | ||||||||
| Holm adjust | P values corrected by Holm–Bonferroni method for multiple hypothesis testing | ||||||||
| FDR | P value corrected by false discovery rate (FDR) method for multiple hypothesis testing | ||||||||
| Impact | Impact value of metabolic pathway topology analysis | ||||||||
| Hits cpd | The names and KEGG IDs of differential metabolites hit the pathway | ||||||||
| Total cpd | All metabolite names and KEGG IDs contained in this pathway | ||||||||
Table 4.
Enrichment analysis results based on mass spectrometry combined with gas phase.
| Pathway | Total | Hits | Raw p | −ln(p) | Holm adjust | FDR | Impact | Hits cpd | Total cpd |
|---|---|---|---|---|---|---|---|---|---|
| Pyrimidine metabolism | 41 | 5 | 0.0013 | 6.6293 | 0.11 | 0.108 | 0.09731 | Deoxyuridine cpd: C00526; uracil cpd: C00106; beta-alanine cpd: C00099; thymine cpd: C00178; 3-aminoisobutanoic acid cpd: C05145 | Thioredoxin cpd: C00342; uridine 5′-diphosphate cpd: C00015; L-Glutamine cpd: C00064; carbamoylphosphate cpd: C00169; 4,5-dihydroorotic acid cpd: C00337; orotidylic acid cpd: C01103; RNA cpd: C00046; uridine triphosphate cpd: C00075; uridine 5′-monophosphate cpd: C00105; uridine cpd: C00299; dihydrouracil cpd: C00429; ureidopropionic acid cpd: C02642; cytidine triphosphate cpd: C00063; CDP cpd: C00112; cytidine monophosphate cpd: C00055; cytidine cpd: C00475; thioredoxin disulfide cpd: C00343; dCDP cpd: C00705; dCTP cpd: C00458; dCMP cpd: C00239; deoxycytidine cpd: C00881; deoxyuridine triphosphate cpd: C00460; dUDP cpd: C01346; dUMP cpd: C00365; deoxyuridine cpd: C00526; thymidine 5′-triphosphate cpd: C00459; dTDP cpd: C00363; 5-thymidylic acid cpd: C00364; thymidine cpd: C00214; dihydrothymine cpd: C00906; ureidoisobutyric acid cpd: C05100; P1,P4-bis(5′-uridyl) tetraphosphate cpd: C06198; ureidosuccinic acid cpd: C00438; phosphoribosyl pyrophosphate cpd: C00119; orotic acid cpd: C00295; uracil cpd: C00106; beta-alanine cpd: C00099; DNA cpd: C00039; deoxyribose 1-phosphate cpd: C00672; thymine cpd: C00178; 3-aminoisobutanoic acid cpd: C05145 |
| Pantothenate and CoA biosynthesis | 15 | 2 | 0.0384 | 3.2608 | 1 | 1 | 0 | Beta-alanine cpd: C00099; uracil cpd: C00106 | Dephospho-CoA cpd: C00882; pantetheine 4′-phosphate cpd: C01134; pantetheine cpd: C00831; 4-phosphopantothenoylcysteine cpd: C04352; D-pantothenoyl-L-cysteine cpd: C04079; d-4′-phosphopantothenate cpd: C03492; L-cysteine cpd: C00097; pantothenic acid cpd: C00864; ureidopropionic acid cpd: C02642; dihydrouracil cpd: C00429; L-valine cpd: C00183; coenzyme a cpd: C00010; beta-alanine cpd: C00099; uracil cpd: C00106; alpha-ketoisovaleric acid cpd: C00141 |
| Beta-alanine metabolism | 17 | 2 | 0.0484 | 3.0283 | 1 | 1 | 0.44444 | Beta-alanine cpd: C00099; uracil cpd: C00106 | Acrylyl-CoA cpd: C00894; 3-hydroxypropionyl-CoA cpd: C05668; hydroxypropionic acid cpd: C01013; malonyl-CoA cpd: C00083; beta-alanine cpd: C00099; L-aspartic acid cpd: C00049; spermine cpd: C00750; 1,3-diaminopropane cpd: C00986; 3-aminopropionaldehyde cpd: C05665; ureidopropionic acid cpd: C02642; dihydrouracil cpd: C00429; anserine cpd: C01262; propionyl-CoA cpd: C00100; Acetyl-CoA cpd: C00024; malonic semialdehyde cpd: C00222; spermidine cpd: C00315; uracil cpd: C00106 |
| Starch and sucrose metabolism | 19 | 2 | 0.0593 | 2.8253 | 1 | 1 | 0.07451 | D-maltose cpd: C00208; isomaltose cpd: C00252 | beta-D-fructose cpd: C02336; sucrose cpd: C00089; uridine diphosphate glucuronic acid cpd: C00167; uridine diphosphate glucose cpd: C00029; glucose 1-phosphate cpd: C00103; 3-methoxy-4-hydroxyphenylglycol glucuronide cpd: C03033; glucose 6-phosphate cpd: C00668; alpha-D-glucose cpd: C00267; starch cpd: C00369; amylose cpd: C00718; trehalose cpd: C01083; D-maltose cpd: C00208; D-glucose cpd: C00031; dextrin cpd: C00721; isomaltose cpd: C00252; beta-D-fructose 6-phosphate cpd: C05345; UDP-D-xylose cpd: C00190; alpha-D-glucose 1,6-bisphosphate cpd: C01231; D-glucuronic acid cpd: C00191 |
| Propanoate metabolism | 20 | 2 | 0.065 | 2.733 | 1 | 1 | 0 | Beta-alanine cpd: C00099; 2-hydroxybutyric acid cpd: C05984 | (S)-methylmalonic acid semialdehyde cpd: C06002; methylmalonyl-CoA cpd: C00683; propionyl-CoA cpd: C00100; propinol adenylate cpd: C05983; R-methylmalonyl-CoA cpd: C01213; succinic acid cpd: C00042; hydroxypropionic acid cpd: C01013; beta-alanine cpd: C00099; 2-propyn-1-al cpd: C05985; acetyl-CoA cpd: C00024; malonyl-CoA cpd: C00083; 2-hydroxybutyric acid cpd: C05984; acrylyl-CoA cpd: C00894; propionic acid cpd: C00163; succinyl-CoA cpd: C00091; 3-hydroxypropionyl-CoA cpd: C05668; malonic semialdehyde cpd: C00222; propynoic acid cpd: C00804; acetoacetyl-CoA cpd: C00332; 2-ketobutyric acid cpd: C00109 |
| D-glutamine and D-glutamate metabolism | 5 | 1 | 0.1016 | 2.2866 | 1 | 1 | 0 | Oxoglutaric acid cpd: C00026 | L-glutamic acid cpd: C00025; D-glutamine cpd: C00819; L-glutamine cpd: C00064; oxoglutaric acid cpd: C00026; D-glutamic acid cpd: C00217 |
| Sulfur metabolism | 5 | 1 | 0.1016 | 2.2866 | 1 | 1 | 0.3 | Sulfate cpd: C00059 | Phosphoadenosine phosphosulfate cpd: C00053; adenosine phosphosulfate cpd: C00224; sulfite cpd: C00094; sulfate cpd: C00059; adenosine 3′,5′-diphosphate cpd: C00054 |
| Cyanoamino acid metabolism | 6 | 1 | 0.1207 | 2.1145 | 1 | 1 | 0 | Glycine cpd: C00037 | 3-Cyano-L-alanine cpd: C02512; beta-aminopropionitrile cpd: C05670; glycine cpd: C00037; gamma-glutamyl-beta-cyanoalanine cpd: C05711; gamma-glutamyl-beta-aminopropiononitrile cpd: C06114; L-serine cpd: C00065 |
| Methane metabolism | 9 | 1 | 0.1756 | 1.7394 | 1 | 1 | 0 | Glycine cpd: C00037 | S-formylglutathione cpd: C01031; glycine cpd: C00037; 5,10-methylene-THF cpd: C00143; S-(Hydroxymethyl)glutathione cpd: C14180; methanol cpd: C00132; formic acid cpd: C00058; L-serine cpd: C00065; formaldehyde cpd: C00067; 5-methyltetrahydrofolic acid cpd: C00440 |
| Nitrogen metabolism | 9 | 1 | 0.1756 | 1.7394 | 1 | 1 | 0 | Glycine cpd: C00037 | Ammonia cpd: C00014; carbon dioxide cpd: C00011; L-glutamic acid cpd: C00025; L-glutamine cpd: C00064; L-cystathionine cpd: C02291; L-histidine cpd: C00135; carbamoylphosphate cpd: C00169; carbonic acid cpd: C01353; glycine cpd: C00037 |
| Arginine and proline metabolism | 44 | 2 | 0.2382 | 1.4345 | 1 | 1 | 0.04414 | Hydroxyproline cpd: C01157; 4-acetamidobutanoic acid cpd: C02946 | L-glutamine cpd: C00064; ammonia cpd: C00014; carbamoylphosphate cpd: C00169; ornithine cpd: C00077; citrulline cpd: C00327; L-aspartic acid cpd: C00049; argininosuccinic acid cpd: C03406; L-arginine cpd: C00062; L-glutamic acid cpd: C00025; N-acetylornithine cpd: C00437; L-proline cpd: C00148; peptide cpd: C00012; D-proline cpd: C00763; hydroxyproline cpd: C01157; pyrroline hydroxycarboxylic acid cpd: C04281; L-4-hydroxyglutamate semialdehyde cpd: C05938; L-erythro-4-hydroxyglutamate cpd: C05947; N-(o)-hydroxyarginine cpd: C05933; guanidinoacetic acid cpd: C00581; creatine cpd: C00300; gamma-aminobutyric acid cpd: C00334; agmatine cpd: C00179; L-glutamic-gamma-semialdehyde cpd: C01165; L-glutamic acid 5-phosphate cpd: C03287; (S)-1-pyrroline-5-carboxylate cpd: C03912; putrescine cpd: C00134; 4-aminobutyraldehyde cpd: C00555; S-adenosylmethioninamine cpd: C01137; S-adenosylmethionine cpd: C00019; spermidine cpd: C00315; N-Acetylputrescine cpd: C02714; N4-Acetylaminobutanal cpd: C05936; cis-4-hydroxy-D-proline cpd: C03440; Fumaric acid cpd: C00122; urea cpd: C00086; N-Acetyl-L-alanine cpd: C00624; 1-pyrroline-2-carboxylic acid cpd: C03564; D-4-hydroxy-2-oxoglutarate cpd: C05946; nitric oxide cpd: C00533; phosphocreatine cpd: C02305; 4-guanidinobutanoic acid cpd: C01035; spermine cpd: C00750; 4-acetamidobutanoic acid cpd: C02946; 1-pyrroline-4-hydroxy-2-carboxylate cpd: C04282 |
| Glycerolipid metabolism | 18 | 1 | 0.3213 | 1.1355 | 1 | 1 | 0.28098 | Glycerol cpd: C00116 | Triacylglycerol cpd: C00422; acyl-CoA cpd: C00040; 1,2-diacyl-sn-glycerol cpd: C00641; PA(16 : : 0/16 : : 0) cpd: C00416; 1-acyl-sn-glycerol 3-phosphate cpd: C00681; 1-acylglycerol cpd: C01885; glycerol 3-phosphate cpd: C00093; dihydroxyacetone cpd: C00184; glycerol cpd: C00116; lactaldehyde cpd: C05999; D-glyceraldehyde cpd: C00577; glyceric acid cpd: C00258; digalactosyl-diacylglycerol cpd: C06037; fatty acid cpd: C00162; dihydroxyacetone phosphate cpd: C00111; propylene glycol cpd: C00583; 3-phospho-D-glycerate cpd: C00197; 1,2-diacyl-3-beta-D-galactosyl-sn-glycerol cpd: C03692 |
| Citrate cycle (TCA cycle) | 20 | 1 | 0.3501 | 1.0496 | 1 | 1 | 0.06799 | Oxoglutaric acid cpd: C00026 | Enzyme N6-(dihydrolipoyl)lysine cpd: C15973; oxoglutaric acid cpd: C00026; thiamine pyrophosphate cpd: C00068; Enzyme N6-(lipoyl)lysine cpd: C15972; 3-carboxy-1-hydroxypropylthiamine diphosphate cpd: C05381; Succinyl-CoA cpd: C00091; succinic acid cpd: C00042; oxalosuccinic acid cpd: C05379; isocitric acid cpd: C00311; oxalacetic acid cpd: C00036; Acetyl-CoA cpd: C00024; L-malic acid cpd: C00149; cis-aconitic acid cpd: C00417; citric acid cpd: C00158; pyruvic acid cpd: C00022; 2-(a-hydroxyethyl)thiamine diphosphate cpd: C05125; [dihydrolipoyllysine-residue succinyltransferase] S-succinyldihydrolipoyllysine cpd: C16254; Fumaric acid cpd: C00122; S-acetyldihydrolipoamide-E cpd: C16255; phosphoenolpyruvic acid cpd: C00074 |
| Butanoate metabolism | 22 | 1 | 0.3777 | 0.97365 | 1 | 1 | 0 | Oxoglutaric acid cpd: C00026 | 3-Butyn-1-al cpd: C06145; (R)-3-hydroxybutyric acid cpd: C01089; acetoacetic acid cpd: C00164; 3-hydroxy-3-methylglutaryl-CoA cpd: C00356; Acetyl-CoA cpd: C00024; Acetoacetyl-CoA cpd: C00332; (S)-3-hydroxybutanoyl-CoA cpd: C01144; Crotonoyl-CoA cpd: C00877; gamma-aminobutyric acid cpd: C00334; L-glutamic acid cpd: C00025; Butanoyl-CoA cpd: C00136; butanal cpd: C01412; succinic acid semialdehyde cpd: C00232; butyric acid cpd: C00246; oxoglutaric acid cpd: C00026; thiamine pyrophosphate cpd: C00068; pyruvic acid cpd: C00022; 3-butynoate cpd: C06144; 1-butanol cpd: C06142; succinic acid cpd: C00042; 2-hydroxyglutarate cpd: C02630; 2-(a-hydroxyethyl)thiamine diphosphate cpd: C05125 |
| Alanine, aspartate, and glutamate metabolism | 24 | 1 | 0.4042 | 0.90587 | 1 | 1 | 0.06329 | Oxoglutaric acid cpd: C00026 | N-Acetyl-L-aspartic acid cpd: C01042; 2-oxosuccinamate cpd: C02362; L-aspartic acid cpd: C00049; D-aspartic acid cpd: C00402; argininosuccinic acid cpd: C03406; adenylsuccinic acid cpd: C03794; L-Alanine cpd: C00041; succinic acid semialdehyde cpd: C00232; L-glutamic acid cpd: C00025; gamma-aminobutyric acid cpd: C00334; L-Glutamine cpd: C00064; ammonia cpd: C00014; 2-keto-glutaramic acid cpd: C00940; (S)-1-pyrroline-5-carboxylate cpd: C03912; oxalacetic acid cpd: C00036; L-Asparagine cpd: C00152; Fumaric acid cpd: C00122; pyruvic acid cpd: C00022; ureidosuccinic acid cpd: C00438; succinic acid cpd: C00042; oxoglutaric acid cpd: C00026; carbamoylphosphate cpd: C00169; glucosamine 6-phosphate cpd: C00352; 5-phosphoribosylamine cpd: C03090 |
| Galactose metabolism | 26 | 1 | 0.4296 | 0.84494 | 1 | 1 | 0 | Glycerol cpd: C00116 | Stachyose cpd: C01613; D-tagatose 6-phosphate cpd: C01097; D-gal alpha 1->6d-gal alpha 1->6d-glucose cpd: C05404; sucrose cpd: C00089; raffinose cpd: C00492; melibiose cpd: C05402; D-galactose cpd: C00124; galactosylglycerol cpd: C05401; epimelibiose cpd: C05400; melibiitol cpd: C05399; galactinol cpd: C01235; Alpha-D-Glucose cpd: C00267; alpha-lactose cpd: C00243; glucose 1-phosphate cpd: C00103; uridine diphosphategalactose cpd: C00052; uridine diphosphate glucose cpd: C00029; galactose 1-phosphate cpd: C00446; glucose 6-phosphate cpd: C00668; D-tagatose 1,6-bisphosphate cpd: C03785; D-Fructose cpd: C00095; D-glucose cpd: C00031; galactitol cpd: C01697; glycerol cpd: C00116; D-Mannose cpd: C00159; sorbitol cpd: C00794; myoinositol cpd: C00137 |
| Glutathione metabolism | 26 | 1 | 0.4296 | 0.84494 | 1 | 1 | 0.00573 | Glycine cpd: C00037 | R-S-cysteinylglycine cpd: C05729; R-S-glutathione cpd: C02320; glutathione cpd: C00051; NADP cpd: C00006; NADPH cpd: C00005; oxidized glutathione cpd: C00127; gamma-glutamylcysteine cpd: C00669; glycine cpd: C00037; L-cysteine cpd: C00097; L-glutamic acid cpd: C00025; cysteinylglycine cpd: C01419; pyroglutamic acid cpd: C01879; L-amino acid cpd: C00151; 5-L-glutamyl-L-alanine cpd: C03740; RX cpd: C01322; ornithine cpd: C00077; putrescine cpd: C00134; spermidine cpd: C00315; cadaverine cpd: C01672; tryparedoxin cpd: C16663; trypanothione cpd: C02090; S-substituted L-cysteine cpd: C05726; spermine cpd: C00750; aminopropylcadaverine cpd: C16565; tryparedoxin disulfide cpd: C16664; trypanothione disulfide cpd: C03170 |
| Fatty acid elongation in mitochondria | 27 | 1 | 0.4419 | 0.8167 | 1 | 1 | 0 | Palmitic acid cpd: C00249 | Palmityl-CoA cpd: C00154; (2e)-hexadecenoyl-CoA cpd: C05272; (S)-3-hydroxyhexadecanoyl-CoA cpd: C05258; 3-oxohexadecanoyl-CoA cpd: C05259; Acetyl-CoA cpd: C00024; Tetradecanoyl-CoA cpd: C02593; (2e)-tetradecenoyl-CoA cpd: C05273; (S)-3-hydroxytetradecanoyl-CoA cpd: C05260; 3-oxotetradecanoyl-CoA cpd: C05261; Lauroyl-CoA cpd: C01832; (2e)-dodecenoyl-CoA cpd: C03221; (S)-3-hydroxydodecanoyl-CoA cpd: C05262; 3-oxododecanoyl-CoA cpd: C05263; Decanoyl-CoA (n-C10: 0CoA) cpd: C05274; (2e)-decenoyl-CoA cpd: C05275; (S)-hydroxydecanoyl-CoA cpd: C05264; 3-oxodecanoyl-CoA cpd: C05265; Octanoyl-CoA cpd: C01944; (2e)-octenoyl-CoA cpd: C05276; (S)-hydroxyoctanoyl-CoA cpd: C05266; 3-oxooctanoyl-CoA cpd: C05267; Hexanoyl-CoA cpd: C05270; trans-2-hexenoyl-CoA cpd: C05271; (S)-hydroxyhexanoyl-CoA cpd: C05268; 3-oxohexanoyl-CoA cpd: C05269; Butanoyl-CoA cpd: C00136; palmitic acid cpd: C00249 |
| Porphyrin and chlorophyll metabolism | 27 | 1 | 0.4419 | 0.8167 | 1 | 1 | 0 | Glycine cpd: C00037 | Cobinamide cpd: C05774; heme O cpd: C15672; heme cpd: C00032; glycine cpd: C00037; bilirubin diglucuronide cpd: C05787; Cob(I)yrinate a,c diamide cpd: C06505; Fe2 + cpd: C14818; hemoglobin cpd: C01708; biliverdin cpd: C00500; protoporphyrinogen IX cpd: C01079; coproporphyrin III cpd: C03263; uroporphyrinogen III cpd: C01051; hydroxymethylbilane cpd: C01024; porphobilinogen cpd: C00931; 5-aminolevulinic acid cpd: C00430; uroporphyrinogen I cpd: C05766; L-Glutamic acid cpd: C00025; bilirubin cpd: C00486; protoporphyrin IX cpd: C02191; adenosyl cobinamide cpd: C06508; heme a cpd: C15670; D-Urobilinogen cpd: C05791; adenosyl cobyrinic acid a,c diamide cpd: C06506; Fe3+ cpd: C14819; coproporphyrinogen I cpd: C05768; l-glutamyl-tRNA(Glu) cpd: C02987; cytochrome c cpd: C00524 |
| Glycine, serine, and threonine metabolism | 31 | 1 | 0.4886 | 0.71625 | 1 | 1 | 0.26884 | Glycine cpd: C00037 | L-Serine cpd: C00065; choline cpd: C00114; glyceric acid cpd: C00258; betaine cpd: C00719; guanidinoacetic acid cpd: C00581; 3-phospho-D-glycerate cpd: C00197; dimethylglycine cpd: C01026; L-cystathionine cpd: C02291; glycine cpd: C00037; phosphoserine cpd: C01005; sarcosine cpd: C00213; 5,10-methylene-THF cpd: C00143; L-threonine cpd: C00188; lipoylprotein cpd: C02051; aminoacetone cpd: C01888; tetrahydrofolic acid cpd: C00101; S-aminomethyldihydrolipoylprotein cpd: C01242; dihydrolipoylprotein cpd: C02972; D-serine cpd: C00740; betaine aldehyde cpd: C00576; hydroxypyruvic acid cpd: C00168; creatine cpd: C00300; phosphohydroxypyruvic acid cpd: C03232; L-cysteine cpd: C00097; glyoxylic acid cpd: C00048; L-2-amino-3-oxobutanoic acid cpd: C03508; pyruvic acid cpd: C00022; carbon dioxide cpd: C00011; 5-aminolevulinic acid cpd: C00430; pyruvaldehyde cpd: C00546; ammonia cpd: C00014 |
| Valine, leucine, and isoleucine degradation | 38 | 1 | 0.5614 | 0.57739 | 1 | 1 | 0 | Methylmalonic acid cpd: C02170 | Enzyme N6-(lipoyl)lysine cpd: C15972; 2-methyl-1-hydroxybutyl-ThPP cpd: C15978; enzyme N6-(dihydrolipoyl)lysine cpd: C15973; 2-methyl-1-hydroxypropyl-ThPP cpd: C15976; 3-methyl-1-hydroxybutyl-ThPP cpd: C15974; acetyl-CoA cpd: C00024; acetoacetyl-CoA cpd: C00332; acetoacetic acid cpd: C00164; 3-hydroxy-3-methylglutaryl-CoA cpd: C00356; 3-methylcrotonyl-CoA cpd: C03069; 3-hydroxyisovaleryl-CoA cpd: C05998; isovaleryl-CoA cpd: C02939; 3-methyl-2-oxovaleric acid cpd: C00671; thiamine pyrophosphate cpd: C00068; L-valine cpd: C00183; 2-methylacetoacetyl-CoA cpd: C03344; (S)-3-hydroxyisobutyrate cpd: C06001; tiglyl-CoA cpd: C03345; butyryl-CoA cpd: C00630; S-(2-methylbutanoyl)-dihydrolipoamide cpd: C15979; alpha-ketoisovaleric acid cpd: C00141; L-isoleucine cpd: C00407; R-methylmalonyl-CoA cpd: C01213; methylmalonyl-CoA cpd: C00683; propionyl-CoA cpd: C00100; (S)-methylmalonic acid semialdehyde cpd: C06002; (S)-b-aminoisobutyric acid cpd: C03284; 2-methyl-3-hydroxybutyryl-CoA cpd: C04405; (S)-3-hydroxyisobutyryl-CoA cpd: C06000; methacrylyl-CoA cpd: C03460; (S)-2-methylbutanoyl-CoA cpd: C15980; S-(2-methylpropionyl)-dihydrolipoamide-E cpd: C15977; 4-methyl-2-oxopentanoate cpd: C00233; S-(3-methylbutanoyl)-dihydrolipoamide-E cpd: C15975; L-leucine cpd: C00123; 3-methylglutaconyl-CoA cpd: C03231; succinyl-CoA cpd: C00091; methylmalonic acid cpd: C02170 |
| Fatty acid metabolism | 39 | 1 | 0.5709 | 0.56053 | 1 | 1 | 0 | Palmitic acid cpd: C00249 | Palmityl-CoA cpd: C00154; hexanoyl-CoA cpd: C05270; butanoyl-CoA cpd: C00136; acetyl-CoA cpd: C00024; (S)-3-hydroxybutanoyl-CoA cpd: C01144; cis,cis-3,6-dodecadienoyl-CoA cpd: C05280; (S)-hydroxyhexanoyl-CoA cpd: C05268; (S)-hydroxyoctanoyl-CoA cpd: C05266; octanoyl-CoA cpd: C01944; (S)-hydroxydecanoyl-CoA cpd: C05264; decanoyl-CoA (n-C10: 0CoA) cpd: C05274; (S)-3-hydroxydodecanoyl-CoA cpd: C05262; lauroyl-CoA cpd: C01832; primary alcohol cpd: C00226; glutaryl-CoA cpd: C00527; (S)-3-hydroxytetradecanoyl-CoA cpd: C05260; tetradecanoyl-CoA cpd: C02593; fatty acid cpd: C00162; (S)-3-hydroxyhexadecanoyl-CoA cpd: C05258; palmitic acid cpd: C00249; (2E)-hexadecenoyl-CoA cpd: C05272; trans-2-hexenoyl-CoA cpd: C05271; crotonoyl-CoA cpd: C00877; acetoacetyl-CoA cpd: C00332; trans,cis-Lauro-2,6-dienoyl-CoA cpd: C05279; coenzyme A cpd: C00010; 3-oxohexanoyl-CoA cpd: C05269; 3-oxooctanoyl-CoA cpd: C05267; (2E)-octenoyl-CoA cpd: C05276; 3-oxodecanoyl-CoA cpd: C05265; (2E)-decenoyl-CoA cpd: C05275; 3-oxododecanoyl-CoA cpd: C05263; (2E)-dodecenoyl-CoA cpd: C03221; aldehyde cpd: C00071; 3-oxotetradecanoyl-CoA cpd: C05261; (2E)-tetradecenoyl-CoA cpd: C05273; omega-hydroxy fatty acid cpd: C03547; 3-oxohexadecanoyl-CoA cpd: C05259; L-palmitoylcarnitine cpd: C02990 |
| Tryptophan metabolism | 40 | 1 | 0.5803 | 0.5443 | 1 | 1 | 0 | N-acetylserotonin cpd: C00978 | L-tryptophan cpd: C00078; melatonin cpd: C01598; serotonin cpd: C00780; 5-hydroxykynurenamine cpd: C05638; 5-hydroxykynurenine cpd: C05651; 5-hydroxy-L-tryptophan cpd: C00643; L-formylkynurenine cpd: C02700; acetoacetyl-CoA cpd: C00332; (S)-3-hydroxybutanoyl-CoA cpd: C01144; crotonoyl-CoA cpd: C00877; glutaryl-CoA cpd: C00527; oxoadipic acid cpd: C00322; 2-amino-3-carboxymuconic acid semialdehyde cpd: C04409; 3-hydroxyanthranilic acid cpd: C00632; L-kynurenine cpd: C00328; formylanthranilic acid cpd: C05653; L-3-hydroxykynurenine cpd: C03227; 3-hydroxykynurenamine cpd: C05636; indoleacetaldehyde cpd: C00637; 5-hydroxy-N-formylkynurenine cpd: C05648; 5-hydroxyindoleacetaldehyde cpd: C05634; tryptamine cpd: C00398; indoleacrylic acid cpd: C00331; acetyl-N-formyl-5-methoxykynurenamine cpd: C05642; 6-hydroxymelatonin cpd: C05643; N-acetylserotonin cpd: C00978; formyl-5-hydroxykynurenamine cpd: C05647; 4,6-dihydroxyquinoline cpd: C05639; acetyl-CoA cpd: C00024; 2-aminomuconic acid semialdehyde cpd: C03824; 2-aminobenzoic acid cpd: C00108; L-tryptophanyl-tRNA(Trp) cpd: C03512; cinnavalininate cpd: C05640; 4-(2-amino-3-hydroxyphenyl)-2,4-dioxobutanoic acid cpd: C05645; 4-(2-aminophenyl)-2,4-dioxobutanoic acid cpd: C01252; 4,8-dihydroxyquinoline cpd: C05637; indoleacetic acid cpd: C00954; 5-hydroxyindoleacetic acid cpd: C05635; N-methylserotonin cpd: C06212; N-methyltryptamine cpd: C06213 |
| Biosynthesis of unsaturated fatty acids | 42 | 1 | 0.5983 | 0.51359 | 1 | 1 | 0 | Palmitic acid cpd: C00249 | (13Z,16Z)-docosadi-13,16-enoyl-CoA cpd: C16645; tetracosenoyl-CoA cpd: C16532; docosenoyl-CoA cpd: C16531; icosenoyl-CoA cpd: C16530; tetracosanoyl-CoA cpd: C16529; docosanoyl-CoA cpd: C16528; (7Z,10Z,13Z,16Z)-docosatetraenoyl-CoA cpd: C16170; (11Z,14Z)-icosadienoyl-CoA cpd: C16180; (7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl-CoA cpd: C16166; (11Z,14Z,17Z)-icosatrienoyl-CoA cpd: C16179; palmityl-CoA cpd: C00154; stearoyl-CoA cpd: C00412; eicosanoyl-CoA cpd: C02041; oleoyl-CoA cpd: C00510; linoleoyl-CoA cpd: C02050; arachidonyl-CoA cpd: C02249; 8,11,14-eicosatrienoyl-CoA cpd: C03595; gamma-linolenoyl-CoA cpd: C03035; (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-CoA cpd: C16169; (5Z,8Z,11Z,14Z,17Z)-icosapentaenoyl-CoA cpd: C16165; alpha-linolenoyl-CoA cpd: C16162; 13,16-docosadienoic acid cpd: C16533; nervonic acid cpd: C08323; erucic acid cpd: C08316; icosenoic acid cpd: C16526; tetracosanoic acid cpd: C08320; behenic acid cpd: C08281; 7,10,13,16-docosatetraenoic acid cpd: C16527; icosadienoic acid cpd: C16525; clupanodonic acid cpd: C16513; icosatrienoic acid cpd: C16522; palmitic acid cpd: C00249; stearic acid cpd: C01530; arachidic acid cpd: C06425; oleic acid cpd: C00712; linoleic acid cpd: C01595; arachidonic acid cpd: C00219; 8,11,14-eicosatrienoic acid cpd: C03242; gamma-linolenic acid cpd: C06426; (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid cpd: C06429; eicosapentaenoic acid cpd: C06428; alpha-linolenic acid cpd: C06427 |
| Fatty acid biosynthesis | 43 | 1 | 0.6071 | 0.49905 | 1 | 1 | 0 | Palmitic acid cpd: C00249 | Tetradecanoyl-[acp] cpd: C05761; malonyl-[acyl-carrier protein] cpd: C01209; hexadecanoyl-[acp] cpd: C05764; octadecanoyl-[acyl-carrier protein] cpd: C04088; oleoyl-[acyl-carrier protein] cpd: C01203; dodecanoyl-[acyl-carrier protein] cpd: C05223; decanoyl-[acp] cpd: C05755; octanoyl-[acp] cpd: C05752; Hexanoyl-[acp] cpd: C05749; butyryl-[acp] cpd: C05745; trans-hexadec-2-enoyl-[acp] cpd: C05763; (3R)-3-hydroxypalmitoyl-[acyl-carrier protein] cpd: C04633; 3-oxohexadecanoyl-[acp] cpd: C05762; trans-tetradec-2-enoyl-[acp] cpd: C05760; (3R)-3-hydroxytetradecanoyl-[acyl-carrier protein] cpd: C04688; 3-oxotetradecanoyl-[acp] cpd: C05759; trans-dodec-2-enoyl-[acp] cpd: C05758; (R)-3-hydroxydodecanoyl-[acp] cpd: C05757; 3-oxododecanoyl-[acp] cpd: C05756; trans-Dec-2-enoyl-[acp] cpd: C05754; (3R)-3-hydroxydecanoyl-[acyl-carrier protein] cpd: C04619; 3-oxodecanoyl-[acp] cpd: C05753; trans-Oct-2-enoyl-[acp] cpd: C05751; (3R)-3-hydroxyoctanoyl-[acyl-carrier protein] cpd: C04620; 3-oxooctanoyl-[acp] cpd: C05750; trans-Hex-2-enoyl-[acp] cpd: C05748; (R)-3-hydroxyhexanoyl-[acp] cpd: C05747; 3-oxohexanoyl-[acp] cpd: C05746; but-2-enoyl-[acyl-carrier protein] cpd: C04246; (3R)-3-hydroxybutanoyl-[acyl-carrier protein] cpd: C04618; acetyl-[acyl-carrier protein] cpd: C03939; Malonyl-CoA cpd: C00083; acetyl-CoA cpd: C00024; acyl-carrier protein cpd: C00229; Holo-[carboxylase] cpd: C06250; carboxybiotin-carboxyl-carrier protein cpd: C04419; myristic acid cpd: C06424; 3-oxostearoyl-[acp] cpd: C16219; stearic acid cpd: C01530; oleic acid cpd: C00712; dodecanoic acid cpd: C02679; palmitic acid cpd: C00249; acetoacetyl-[acp] cpd: C05744 |
| Primary bile acid biosynthesis | 46 | 1 | 0.6323 | 0.45839 | 1 | 1 | 0.02976 | Glycine cpd: C00037 | Cholesterol cpd: C00187; cholest-5-ene-3beta,26-diol cpd: C15610; 25-hydroxycholesterol cpd: C15519; 7 alpha,26-dihydroxy-4-cholesten-3-one cpd: C17336; 4-cholesten-7alpha,12alpha-diol-3-one cpd: C17339; 7a-hydroxy-cholestene-3-one cpd: C05455; 5-b-cholestane-3a , 7a ,12a-triol cpd: C05454; (25R)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl-CoA cpd: C15613; (25S)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl-CoA cpd: C17343; 3a,7a,12a-trihydroxy-5b-cholest-24-enoyl-CoA cpd: C05460; 3a,7a,12a-trihydroxy-5b-24-oxocholestanoyl-CoA cpd: C05467; 3a,7a-dihydroxy-5b-24-oxocholestanoyl-CoA cpd: C05449; chenodeoxycholoyl-CoA cpd: C05337; glycine cpd: C00037; taurine cpd: C00245; 3alpha,7alpha,12alpha,26-tetrahydroxy-5beta-cholestane cpd: C05446; 3a,7a,12a-trihydroxy-5b-cholestan-26-al cpd: C01301; 3 beta,7 alpha-dihydroxy-5-cholestenoate cpd: C17335; 7-a,27-dihydroxycholesterol cpd: C06341; 7a-Hydroxycholesterol cpd: C03594; 7-a,25-dihydroxycholesterol cpd: C15520; Choloyl-CoA cpd: C01794; 24-hydroxycholesterol cpd: C13550; 3alpha,7alpha-dihydroxy-5beta-cholestanate cpd: C04554; 3a,7a-dihydroxy-5b-cholestane cpd: C05452; 3 alpha,7 alpha,26-trihydroxy-5beta-cholestane cpd: C05444; 3a,7a-dihydroxy-5b-cholestan-26-al cpd: C05445; (25R)-3alpha,7alpha-dihydroxy-5beta-cholestanoyl-CoA cpd: C17345; (25S)-3alpha,7alpha-dihydroxy-5beta-cholestanoyl-CoA cpd: C17346; 3a,7a-dihydroxy-5b-cholest-24-enoyl-CoA cpd: C05447; 3a,7a,12a-Trihydroxy-5b-cholestanoic acid cpd: C04722; 3a,7a,12a-trihydroxy-5b-cholestanoyl-CoA cpd: C05448; 3a,7a,12a,24-tetrahydroxy-5b-cholestanoyl-CoA cpd: C05450; 3 beta-hydroxy-5-cholestenoate cpd: C17333; (24S)-cholest-5-ene-3beta,7alpha,24-triol cpd: C15518; 7 alpha-hydroxy-3-oxo-4-cholestenoate cpd: C17337; 7a,12a-dihydroxy-5b-cholestan-3-one cpd: C05453; 7a-hydroxy-5b-cholestan-3-one cpd: C05451; chenodeoxycholic acid cpd: C02528; chenodeoxycholic acid glycine conjugate cpd: C05466; taurochenodesoxycholic acid cpd: C05465; 7alpha,25-dihydroxy-4-cholesten-3-one cpd: C17332; cholic acid cpd: C00695; glycocholic acid cpd: C01921; taurocholic acid cpd: C05122; 7 alpha,24-dihydroxy-4-cholesten-3-one cpd: C17331 |
|
| |||||||||
| Purine metabolism | 68 | 1 | 0.7749 | 0.25507 | 1 | 1 | 0 | Sulfate cpd: C00059 | Guanosine diphosphate cpd: C00035; xanthine cpd: C00385; D-ribulose 5-phosphate cpd: C00117; phosphoribosyl pyrophosphate cpd: C00119; L-glutamine cpd: C00064; 5-phosphoribosylamine cpd: C03090; glycineamideribotide cpd: C03838; phosphoribosylformylglycineamidine cpd: C04640; AICAR cpd: C04677; SAICAR cpd: C04823; 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate cpd: C04751; RNA cpd: C00046; cyclic AMP cpd: C00575; adenosine triphosphate cpd: C00002; dATP cpd: C00131; ADP cpd: C00008; dADP cpd: C00206; adenosine monophosphate cpd: C00020; adenylsuccinic acid cpd: C03794; inosinic acid cpd: C00130; adenosine cpd: C00212; deoxyadenosine monophosphate cpd: C00360; deoxyadenosine cpd: C00559; deoxyinosine cpd: C05512; xanthosine cpd: C01762; IDP cpd: C00104; guanosine monophosphate cpd: C00144; xanthylic acid cpd: C00655; hypoxanthine cpd: C00262; inosine cpd: C00294; guanine cpd: C00242; deoxyguanosine cpd: C00330; allantoic acid cpd: C00499; uric acid cpd: C00366; 5-hydroxyisourate cpd: C11821; guanosine 3′-diphosphate 5′-triphosphate cpd: C04494; guanosine triphosphate cpd: C00044; 2′-deoxyguanosine 5′-monophosphate cpd: C00362; dGDP cpd: C00361; guanosine cpd: C00387; dGTP cpd: C00286; cyclic GMP cpd: C00942; sulfate cpd: C00059; adenosine phosphosulfate cpd: C00224; phosphoadenosine phosphosulfate cpd: C00053; 5′-Phosphoribosyl-N-formylglycinamide cpd: C04376; inosine triphosphate cpd: C00081; xanthosine 5-triphosphate cpd: C00700; diadenosine tetraphosphate cpd: C01260; P1,P4-bis(5′-xanthosyl) tetraphosphate cpd: C04392; adenosine diphosphate ribose cpd: C00301; adenine cpd: C00147; dIDP cpd: C01344; 2′-deoxyinosine triphosphate cpd: C01345; diadenosine triphosphate cpd: C06197; phosphoribosyl formamidocarboxamide cpd: C04734; 5-hydroxy-2-oxo-4-ureido-2,5-dihydro-1H-imidazole-5-carboxylate cpd: C12248; 5-aminoimidazole ribonucleotide cpd: C03373; DNA cpd: C00039; ammonia cpd: C00014; urea cpd: C00086; (S)-ureidoglycolic acid cpd: C00603; guanosine 3′,5′-bis(diphosphate) cpd: C01228; adenosine 3′,5′-diphosphate cpd: C00054; diguanosine tetraphosphate cpd: C01261; dIMP cpd: C06196; 5-amino-4-imidazolecarboxyamide cpd: C04051; (S) (+)-allantoin cpd: C02350 |
| Aminoacyl-tRNA biosynthesis | 69 | 1 | 0.7799 | 0.24863 | 1 | 1 | 0 | Glycine cpd: C00037 | L-asparagine cpd: C00152; tRNA(Asn) cpd: C01637; L-histidine cpd: C00135; tRNA(His) cpd: C01643; L-phenylalanine cpd: C00079; tRNA(Phe) cpd: C01648; L-arginine cpd: C00062; tRNA(Arg) cpd: C01636; L-glutamine cpd: C00064; tRNA(Gln) cpd: C01640; L-cysteine cpd: C00097; tRNA(Cys) cpd: C01639; glycine cpd: C00037; tRNA(Gly) cpd: C01642; tRNA(Asp) cpd: C01638; L-aspartic acid cpd: C00049; L-serine cpd: C00065; tRNA(Ser) cpd: C01650; L-methionine cpd: C00073; tRNA(Met) cpd: C01647; L-valine cpd: C00183; tRNA(Val) cpd: C01653; L-alanine cpd: C00041; tRNA(Ala) cpd: C01635; L-lysine cpd: C00047; tRNA(Lys) cpd: C01646; L-isoleucine cpd: C00407; tRNA(Ile) cpd: C01644; tRNA(Leu) cpd: C01645; L-leucine cpd: C00123; L-threonine cpd: C00188; tRNA(Thr) cpd: C01651; tRNA(Trp) cpd: C01652; L-tryptophan cpd: C00078; N10-formyl-THF cpd: C00234; L-methionyl-tRNA cpd: C02430; L-tyrosine cpd: C00082; tRNA(Tyr) cpd: C00787; L-proline cpd: C00148; tRNA(Pro) cpd: C01649; L-glutamic acid cpd: C00025; tRNA(Glu) cpd: C01641; glutaminyl-tRNA cpd: C02282; L-asparaginyl-tRNA(Asn) cpd: C03402; tRNA(Sec) cpd: C16636; L-seryl-tRNA(Sec) cpd: C06481; O-phosphoseryl-tRNA(Sec) cpd: C16638; L-histidyl-tRNA(His) cpd: C02988; L-phenylalanyl-tRNA(Phe) cpd: C03511; L-arginyl-tRNA(Arg) cpd: C02163; L-cysteinyl-tRNA(Cys) cpd: C03125; Glycyl-tRNA(Gly) cpd: C02412; L-aspartyl-tRNA(Asp) cpd: C02984; L-seryl-tRNA(Ser) cpd: C02553; L-valyl-tRNA(Val) cpd: C02554; L-alanyl-tRNA cpd: C00886; L-lysyl-tRNA cpd: C01931; L-isoleucyl-tRNA(Ile) cpd: C03127; L-leucyl-tRNA cpd: C02047; L-threonyl-tRNA(Thr) |
| cpd: C02992; L-tryptophanyl-tRNA(Trp) cpd: C03512; tetrahydrofolic acid cpd: C00101; N-formylmethionyl-tRNA cpd: C03294; L-tyrosyl-tRNA(Tyr) cpd: C02839; L-prolyl-tRNA(Pro) cpd: C02702; L-glutamyl-tRNA(Glu) cpd: C02987; L-glutamyl-tRNA(Gln) cpd: C06112; L-aspartyl-tRNA(Asn) cpd: C06113; L-selenocysteinyl-tRNA(Sec) cpd: C06482 | |||||||||
| Pathway | Metabolic pathway name | ||||||||
| Total | The number of metabolites in this pathway | ||||||||
| Hits | The number of differential metabolites hit this pathway | ||||||||
| Raw p | P value of metabolic pathway enrichment analysis | ||||||||
| −ln (p) | Minus log base E of P | ||||||||
| Holm adjust | P values corrected by Holm–Bonferroni method for multiple hypothesis testing | ||||||||
| FDR | P value corrected by false discovery rate (FDR) method for multiple hypothesis testing | ||||||||
| Impact | Impact value of metabolic pathway topology analysis | ||||||||
| Hits cpd | The names and KEGG IDs of differential metabolites hit the pathway | ||||||||
| Total cpd | All metabolite names and KEGG IDs contained in this pathway | ||||||||
Figure 3.

Metabolic pathway enrichment analysis of differential metabolites. (a) Pathway analysis of group M versus group T based on mass spectrometry combined with high-performance liquid chromatography. (b) Pathway analysis of group M versus group T based on mass spectrometry combined with gas chromatography. Each bubble represents a metabolic pathway; the bubble size represents the influence factor, the larger the size, the larger the influence factor; the vertical coordinate of the bubble and the color of the bubble indicate the P value of the enrichment analysis; the darker the color, the smaller the P value, the more significant the enrichment.
3.4. Comparison of Serum Inflammatory Factor Levels in Three Groups of Mice
Finally, we observed the serum inflammatory factor levels in the three groups of mice to determine the effect of Yanghe decoction on inflammatory factors in mice with Hashimoto's thyroiditis. The results showed that the serum inflammatory factor IL-35 was significantly lower and IL-6 was significantly higher in mice of group M than group C, while the serum inflammatory factor IL-35 was significantly higher and IL-6 was significantly lower in mice of group T than group M. The results showed that the serum inflammatory factor IL-35 was significantly lower and IL-6 was significantly lower in mice of group T than group C. See Figure 4.
Figure 4.

Comparison of serum levels of inflammatory factors IL-35 and IL-6 in three groups of mice.
4. Discussion
Metabolism plays a central role as a signaling molecule, immunomodulator, endogenous toxin, and environmental sensor in all areas of biology, from ecology to bioengineering to cancer. Each of these fields is now increasingly being studied from a metabolic perspective. And these studies are valuable from a big picture perspective [11]. The metabolome is a collection of small-molecule chemical entities involved in metabolism and has traditionally been studied to identify biomarkers for the diagnosis and prediction of disease. Nowadays, the value of metabolomic analysis has been redefined from a simple biomarker identification tool to a technique for discovering active drivers of biological processes [12]. Metabolomics is the high-throughput characterization of metabolites from cells, organs, tissues, or biofluids using advanced analytical chemistry techniques [13]. NMR and mass spectrometry are commonly used in metabolomics; NMR is highly reproducible and quantitative, has a simple sample preparation protocol, and is capable of measuring analytes in a variety of solvent conditions, but it has low sensitivity. In contrast, the high sensitivity and low detection limits of mass spectrometry enable the detection of subtle metabolic changes that are not visible with NMR [14]. In this experiment, a total of 38 differential metabolites were screened based on mass spectrometry coupled with the high-performance liquid phase, 120 differential metabolites were screened based on mass spectrometry coupled with gas phase, and a total of α-glucose and β-glucose were analyzed based on NMR test results.
Measuring metabolite concentrations by metabolomics only tells half the story. Equally important is to understand pathway activity, which can be quantified as the flow of material per unit time, i.e., metabolic flux. In this experiment, we took intersections of pathways enriched by differential metabolites in the M and T groups for both mass spectrometry coupled with high-performance liquid and gas phases, yielding a total of five common pathways, namely, amino acid tRNA biosynthesis, D-glutamine and D-glutamate metabolism, tryptophan metabolism, nitrogen metabolism, and arginine and proline metabolism.
Amino tRNA is a substrate for translation and plays a key role in determining how the genetic code is interpreted into amino acids. The function of aminyl-tRNA synthesis is to precisely match amino acids to tRNAs containing the corresponding anticodons [15]. Aminyl-tRNA synthetase is essential for the physical interpretation of the genetic code [16], and in addition to its function in protein synthesis, it is involved in various cellular processes such as immune and inflammatory responses, angiogenesis, and apoptosis [17,18]. Just one study showed that the pentose phosphate pathway, amyl-tRNA biosynthesis, and pyrimidine metabolism are the main pathways altered in hypothyroidism [19]. Glutamate is a key excitatory neurotransmitter responsible for maintaining cognitive function and neuronal plasticity [20], while metabolites associated with glutamate metabolism, 2-ketoglutarate, L-aspartate, and fumarate are associated with the gut microbiota, and their alterations may affect human health [21]. Some studies have indicated that glycerophospholipid, glutamine, and glutamate metabolism, and related metabolites are potential key targets for common molecular mechanisms linking HIV to NCDs through inflammation and oxidative stress [22]. Tryptophan is an essential aromatic amino acid consisting of a β-carbon attached to the 3-position of the indole group. Although tryptophan is the least abundant amino acid in proteins and cells, it is a biosynthetic precursor for a large number of microbial and host metabolites [23,24]. Tryptophan metabolism in the intestine is the direct conversion of tryptophan by intestinal microorganisms into several molecules, such as indoles and their derivatives. And many of these indole derivatives, in turn, are ligands for aryl hydrocarbon receptors [25]. Aryl hydrocarbon receptor signaling is thought to be a key component of the immune response at the barrier site and thus can maintain intestinal homeostasis by acting on epithelial renewal, barrier integrity, and many immune cell types [26]. Arginine is a nonessential or semiessential amino acid that plays an important role in a variety of biological functions including cell proliferation, survival, and protein synthesis. It is also a precursor for the production of nitric oxide, polyamines, proline, creatinine, and glutamate. As a multifunctional amino acid, arginine plays an important role in physical health by being involved in tissue damage and chronic metabolic diseases [27]. Arginine has also been associated with endothelial function, inflammation, and airway hyperresponsiveness [28]. Just one study indicated that arginine and proline metabolic pathways are related to asthma pathogenesis [29]. The above combined with the results of the present experiment could suggest that Yanghe decoction may maintain homeostasis by altering the relevant metabolic pathways and thus improving the disease. In addition, the above pathways have shown relevance to inflammation as well as immune cells. For this reason, we also investigated the effect of Yanghe decoction.
Inflammation is a comprehensive physiological response to tissue damage, which is caused by physical injury, infection, exposure to toxins, or other types of trauma [30]. There is growing evidence that inflammation is a major factor in the progression of many diseases, including autoimmune thyroiditis [31]. The results of the present study showed that serum inflammatory factor IL-35 was significantly lower and IL-6 was significantly higher in mice in the model group compared with the normal control group, whereas serum inflammatory factor IL-35 was significantly higher and IL-6 was significantly lower in mice treated based on Yanghe decoction compared with the model group. This may be due to the effect of one or a combination of herbs in the composition of Yanghe decoction. Deer antler tablets have antifatigue, anti-inflammatory, and analgesic effects, while deer antler peptides are the main active ingredients obtained by isolation from deer antler tablets [32]. It has been shown that in osteoblasts, antler peptides block TNF-α-mediated inhibition of osteoblastogenesis and inhibit osteoclastogenesis through the nuclear factor-κB (NF-κB)/p65 pathway. In addition, deer antler peptides reduce levels of interleukin 1β and interleukin 6, as well as oxidative responses induced by increased catalase activity and reduced malondialdehyde levels [33]. Previous studies have also indicated that Yanghe decoction may improve the symptoms of Hashimoto's thyroiditis and reduce inflammation [34]. This could suggest that Yanghe decoction can effectively reduce the inflammatory response in Hashimoto's thyroiditis, but whether the specific mechanism is related to metabolic pathways remains to be explored.
5. Conclusion
In summary, we detected multiple metabolites that can be altered by Yanghe decoction by NMR and mass spectrometry coupled with gas or liquid chromatography, and most of them were related to aminyl-tRNA biosynthesis, D-glutamine and D-glutamine metabolism, tryptophan metabolism, nitrogen metabolism, and arginine and proline metabolic pathways. In addition, Yanghe decoction can effectively reduce serum inflammatory factor levels in mice with Hashimoto's thyroiditis.
Although we identified the metabolites that can be altered by Yanghe decoction and the pathways that are highly affected, there are still shortcomings in this study. We only observed the metabolomic profile of plasma, and further studies should evaluate serum, urine, cerebrospinal fluid, and brain samples to accurately reflect the pathological changes in Hashimoto's thyroiditis and the therapeutic mechanisms of Yanghe decoction.
Data Availability
All data generated or analyzed during this study are included in this article.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
References
- 1.Lai X., Xia Y., Zhang B., Li J., Jiang Y. A meta-analysis of Hashimoto’s thyroiditis and papillary thyroid carcinoma risk. Oncotarget . 2017;8(37):62424. doi: 10.18632/oncotarget.18620. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Ralli M., Angeletti D., Fiore M., et al. Hashimoto’s thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmunity Reviews . 2020;19 doi: 10.1016/j.autrev.2020.102649.102649 [DOI] [PubMed] [Google Scholar]
- 3.Min Y., Wang X., Chen H., Yin G. The exploration of Hashimoto’s Thyroiditis related miscarriage for better treatment modalities. International Journal of Medical Sciences . 2020;17(16):2402–2415. doi: 10.7150/ijms.48128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Akamizu T., Amino N. J. E. Hashimoto’s Thyroiditis. 2017. https://pubmed.ncbi.nlm.nih.gov/25905412/
- 5.Graceffa G., Patrone R., Vieni S., et al. Association between Hashimoto’s thyroiditis and papillary thyroid carcinoma: a retrospective analysis of 305 patients. BMC Endocrine Disorders . 2019;19:1–6. doi: 10.1186/s12902-019-0351-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Mao D., Feng L., Gong H. J. E.-B. C. The antitumor and immunomodulatory effect of Yanghe decoction in breast cancer is related to the modulation of the JAK/STAT signaling pathway. Evidence-Based Complementary and Alternative Medicine . 2018;2018:9. doi: 10.1155/2018/8460526.8460526 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Xu X., Wan Y., Gong L., Ma Z., Xu T. J. M. Chinese herbal medicine Yanghe decoction for knee osteoarthritis: a protocol for systematic review and meta-analysis. Medicine . 2020;99 doi: 10.1097/md.0000000000021877. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Xia H., Cao D., Yang F., et al. Jiawei Yanghe decoction ameliorates cartilage degradation in vitro and vivo via Wnt/β-catenin signaling pathway. Biomedicine & Pharmacotherapy . 2020;122 doi: 10.1016/j.biopha.2019.109708.109708 [DOI] [PubMed] [Google Scholar]
- 9.Zeng L., Yang K. Exploring the pharmacological mechanism of Yanghe Decoction on HER2-positive breast cancer by a network pharmacology approach. Journal of Ethnopharmacology . 2017;199:68–85. doi: 10.1016/j.jep.2017.01.045. [DOI] [PubMed] [Google Scholar]
- 10.Li J., Liu X., Chen H., et al. Multi-targeting chemoprevention of Chinese herb formula Yanghe Huayan decoction on experimentally induced mammary tumorigenesis. BMC Complementary and Alternative Medicine . 2019;19:48–15. doi: 10.1186/s12906-019-2456-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Jang C., Chen L., Rabinowitz J. D. Metabolomics and isotope tracing. Cell . 2018;173(4):822–837. doi: 10.1016/j.cell.2018.03.055. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Rinschen M. M., Ivanisevic J., Giera M., Siuzdak G. Identification of bioactive metabolites using activity metabolomics. Nature Reviews Molecular Cell Biology . 2019;20(6):353–367. doi: 10.1038/s41580-019-0108-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Wishart D. S. Metabolomics for investigating physiological and pathophysiological processes. Physiological Reviews . 2019;99:1819–1875. doi: 10.1152/physrev.00035.2018. [DOI] [PubMed] [Google Scholar]
- 14.Riekeberg E., Powers R. J. F. New frontiers in metabolomics: from measurement to insight. F1000Res . 2017;6 doi: 10.12688/f1000research.11495.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Ibba M., Söll D. Aminoacyl-tRNA synthesis. Annual Review of Biochemistry . 2000;69(1):617–650. doi: 10.1146/annurev.biochem.69.1.617. [DOI] [PubMed] [Google Scholar]
- 16.Francklyn C. S., Mullen P. Progress and challenges in aminoacyl-tRNA synthetase-based therapeutics. Journal of Biological Chemistry . 2019;294(14):5365–5385. doi: 10.1074/jbc.rev118.002956. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Gao X., Guo R., Li Y., et al. Contribution of upregulated aminoacyl‐tRNA biosynthesis to metabolic dysregulation in gastric cancer. Journal of Gastroenterology and Hepatology . 2021;36(11):3113–3126. doi: 10.1111/jgh.15592. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Zhang C., Lin X., Zhao Q., et al. YARS as an oncogenic protein that promotes gastric cancer progression through activating PI3K-Akt signaling. Journal of Cancer Research and Clinical Oncology . 2020;146(2):329–342. doi: 10.1007/s00432-019-03115-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Muñoz-Prieto A., González-Arostegui L. G., Rubić I., et al. Untargeted metabolomic profiling of serum in dogs with hypothyroidism. Research in Veterinary Science . 2021;136:6–10. doi: 10.1016/j.rvsc.2021.01.023. [DOI] [PubMed] [Google Scholar]
- 20.Vázquez-Santiago F. J., Noel R. J., Porter J. T., VJJon R.-A. Glutamate metabolism and HIV-associated neurocognitive disorders. Journal of NeuroVirology . 2014;20:315–331. doi: 10.1007/s13365-014-0258-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Wang M., Wan J., Rong H., et al. Alterations in gut glutamate metabolism associated with changes in gut microbiota composition in children with autism spectrum disorder. mSystems . 2019;4:e00321–00318. doi: 10.1128/msystems.00321-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ding Y., Lin H., Chen X., et al. Comprehensive metabolomics profiling reveals common metabolic alterations underlying the four major non-communicable diseases in treated HIV infection. EBioMedicine . 2021;71 doi: 10.1016/j.ebiom.2021.103548.103548 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Alkhalaf L. M., Ryan K. S. Biosynthetic manipulation of tryptophan in bacteria: pathways and mechanisms. Chemistry & Biology . 2015;22(3):317–328. doi: 10.1016/j.chembiol.2015.02.005. [DOI] [PubMed] [Google Scholar]
- 24.Agus A., Planchais J., Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host & Microbe . 2018;23(6):716–724. doi: 10.1016/j.chom.2018.05.003. [DOI] [PubMed] [Google Scholar]
- 25.Hubbard T. D., Murray I. A., Perdew G. H. Indole and tryptophan metabolism: endogenous and dietary routes to Ah receptor activation. Drug Metabolism and Disposition . 2015;43(10):1522–1535. doi: 10.1124/dmd.115.064246. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Lamas B., Natividad J. M., Sokol H. Aryl hydrocarbon receptor and intestinal immunity. Mucosal Immunology . 2018;11(4):1024–1038. doi: 10.1038/s41385-018-0019-2. [DOI] [PubMed] [Google Scholar]
- 27.Zou S., Wang X., Liu P., Ke C., Xu S. Arginine metabolism and deprivation in cancer therapy. Biomedicine & Pharmacotherapy . 2019;118 doi: 10.1016/j.biopha.2019.109210.109210 [DOI] [PubMed] [Google Scholar]
- 28.Liang D., Ladva C. N., Golan R., et al. Perturbations of the arginine metabolome following exposures to traffic-related air pollution in a panel of commuters with and without asthma. Environment International . 2019;127:503–513. doi: 10.1016/j.envint.2019.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Quinn K. D., Schedel M., Nkrumah-Elie Y., et al. Dysregulation of metabolic pathways in a mouse model of allergic asthma. Allergy . 2017;72(9):1327–1337. doi: 10.1111/all.13144. [DOI] [PubMed] [Google Scholar]
- 30.Arulselvan P., Fard M. T., Tan W. S., Gothai S., Fakurazi S., Norhaizan M. E. Role of antioxidants and natural products in inflammation. Oxidative Medicine and Cellular Longevity . 2016;2016:15. doi: 10.1155/2016/5276130.5276130 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Wu D.-H., Xu L., Xie G.-Q., Fan Y.-S., Zhou J. J. E.-bC., Medicine A. The pungent and hot chinese herbs cause heat syndrome in rats by affecting the regulatory T cells. Evidence-Based Complementary and Alternative Medicine . 2019;2019:9. doi: 10.1155/2019/9824906.9824906 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Wu F., Li H., Jin L., et al. Deer antler base as a traditional Chinese medicine: a review of its traditional uses, chemistry and pharmacology. Journal of Ethnopharmacology . 2013;145(2):403–415. doi: 10.1016/j.jep.2012.12.008. [DOI] [PubMed] [Google Scholar]
- 33.Wang Y., Xiao X. Clinical efficacy of modified Yanghe decoction in ankylosing spondylitis: a randomized controlled trial. Medical Science Monitor . 2018;24:2912–2918. doi: 10.12659/msm.909740. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Ma Be, Chen D., Liu Y., et al. Yanghe decoction suppresses the experimental autoimmune thyroiditis in rats by improving NLRP3 inflammasome and immune dysregulation. Frontiers in Pharmacology . 2021;12:p. 1527. doi: 10.3389/fphar.2021.645354. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data generated or analyzed during this study are included in this article.
